University of Dundee

Adaptive homeostasis and the p53 isoform network

Mehta, Sunali; Campbell, Hamish; Drummond, Catherine J.; Li, Kunyu; Murray, Kaisha; Slatter, Tania

Published in:
EMBO Reports

DOI:
[10.15252/embr.202153085](https://doi.org/10.15252/embr.202153085)

Publication date:
2021

Licence:
CC BY

Document Version
Publisher's PDF, also known as Version of record

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):
Mehta, S., Campbell, H., Drummond, C. J., Li, K., Murray, K., Slatter, T., Bourdon, J-C., & Braithwaite, A. W. (2021). Adaptive homeostasis and the p53 isoform network. *EMBO Reports*, 22(12), [e53085].
<https://doi.org/10.15252/embr.202153085>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Adaptive homeostasis and the p53 isoform network

Sunali Mehta^{1,2} , Hamish Campbell¹, Catherine J Drummond^{1,2}, Kunyu Li¹, Kaisha Murray³,
Tania Slatter^{1,2}, Jean-Christophe Bourdon^{3,*} & Antony W Braithwaite^{1,2,**}

Abstract

All living organisms have developed processes to sense and address environmental changes to maintain a stable internal state (homeostasis). When activated, the p53 tumour suppressor maintains cell and organ integrity and functions in response to homeostasis disruptors (stresses) such as infection, metabolic alterations and cellular damage. Thus, p53 plays a fundamental physiological role in maintaining organismal homeostasis. The *TP53* gene encodes a network of proteins (p53 isoforms) with similar and distinct biochemical functions. The p53 network carries out multiple biological activities enabling cooperation between individual cells required for long-term survival of multicellular organisms (animals) in response to an ever-changing environment caused by mutation, infection, metabolic alteration or damage. In this review, we suggest that the p53 network has evolved as an adaptive response to pathogen infections and other environmental selection pressures.

Keywords homeostasis; immune response; inflammation; p53 isoforms; pathogen

Subject Categories Autophagy & Cell Death; Immunology; Signal Transduction

DOI 10.15252/embr.202153085 | Received 18 April 2021 | Revised 12 October 2021 | Accepted 28 October 2021 | Published online 15 November 2021

EMBO Reports (2021) 22: e53085

See the Glossary for abbreviations used in this article.

Introduction: The *TP53* gene—a general homeostatic regulator

Homeostasis is a dynamic equilibrium in which continuous changes occur to maintain internal biochemical conditions for multicellular organisms to live and reproduce in an ever-changing external environment. Any deviation from the limits of the internal conditions triggers a stress response that activates regulatory processes rapidly restoring the initial balance (feedback control) (Alfadda & Sallam, 2012; Marques *et al*, 2016; Horwitz *et al*, 2019). If homeostasis is successful, an animal survives; if unsuccessful, death ensues. However, conflicts can emerge between cellular and organismal fitness, so ensuring cooperation among cells is a major challenge in the

evolution of complex organisms. For example, an individual cell within a tissue may gain a proliferation/fitness advantage by mutation or by better access to nutrients (close to blood vessels) and therefore outgrow the surrounding cells. This may compromise tissue homeostasis and eventually the survival of the animal. This is the case for changes that accrue over time that lead to cancer ((Hanahan & Weinberg, 2011), Fig 1). Similarly, cells and tissues must adapt to both acute and chronic infections and in so doing they acquire multiple changes, which are remarkably similar to those leading to cancer (Fig 1). Such changes suggest that there are common control mechanisms underpinning these adaptive processes. Over the past two decades, studies have identified that the *TP53* gene encodes a network of p53 proteins (p53 isoforms). Despite there being little mechanistic data, several lines of evidence suggest that the p53 network plays a central role in adaptive homeostasis by modulating and coordinating gene expression programmes that ensure cooperation among cells and tissues. In this review, we provide evidence of how different biological processes are regulated by the p53 network to maintain cellular and organismal homeostasis.

Evidence for the *TP53* network contributing to adaptive homeostasis comes from an extensive study aimed at identifying genes required to foster cell cooperation (Dejosez *et al*, 2013). A genome-wide screen was carried out in murine-induced pluripotent stem cells (iPSC) using an shRNA library of 150,000 target genes (Dejosez *et al*, 2013). They identified a small network of genes that cluster closely together and centre on *TP53*. This would be expected as p53 becomes activated (post-translationally modified) by signals emitted from sensors in response to various stresses (e.g. DNA damage, oncogene activation, virus infection, oxidative stress, hypoxia), enabling it to facilitate cellular cooperation allowing cells to adapt to a changing environment in a co-ordinated manner. As p53 is a transcription factor, these adaptations result in alterations to the transcriptional programme to maintain cellular homeostasis (reviewed in Braithwaite & Prives, 2006; Hafner *et al*, 2019). In addition, and consistent with p53 being important in cellular cooperation, phylogenetically, the *TP53* gene is found only in holozoa (Bartas *et al*, 2019), a clade of opisthokont eukaryotes that comprises the animals (moving multicellular organisms) and the motile unicellular organisms, choanoflagellates, Filasterea and Teretospore that demonstrate a degree of multicellularity (King *et al*, 2008).

1 Department of Pathology, School of Medicine, University of Otago, Dunedin, New Zealand

2 Maurice Wilkins Centre for Biodiscovery, University of Otago, Dunedin, New Zealand

3 Dundee Cancer Centre, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK

*Corresponding author. Tel: +44 1382 383285; E-mail: j.bourdon@dundee.ac.uk

**Corresponding author. Tel: +64 3 479 7165; E-mail: antony.braithwaite@otago.ac.nz

Glossary

AKT	Protein kinase B	JNK	c-Jun N-terminal kinase
AMPK	AMP-activated protein kinase	LINE	Long Interspersed Elements
CCL2	Chemokine (C-C motif) ligand 2	LTR	Long terminal repeat
CHARGE	Coloboma, Heart defects, Atresia choanae (also known as choanal atresia), growth Retardation, Genital abnormalities and Ear abnormalities	MAPK	Mitogen-activated protein kinase
CPSF4	Cellular protein cleavage and polyadenylation specificity factor 4	MDM2	Mouse double minute 2 homologue
DDX5	DEAD box protein 5	MEF	Mouse embryonic fibroblasts
DHX15	DEAH-Box Helicase 15	mRNA	messenger RNA
DNA	Deoxyribonucleic acid	NF-κB	Nuclear factor kappa B
dNTPs	Deoxyribonucleotide triphosphates	NS1	Non-structural protein 1
EBV	Epstein–Barr Virus	p16INK4A	Cyclin-dependent kinase 4 inhibitor
EGR1/KLF5	Early growth response protein 1/Kruppel-like factor 5	p21cip1	Cyclin-dependent kinase inhibitor 1
eIF2α	Eukaryotic translation initiation factor 2- α	PD-1	Programmed cell death protein 1
ERV	Endogenous RetroViruses	PD-L1	Programmed cell death 1 ligand 1
GM-CSF	Granulocyte-macrophage colony-stimulating factor	PI3K	Phosphatidylinositol 3-kinase
HASMCs	Human aortic smooth muscle cells	PUMA	p53 upregulated modulator of apoptosis
HGF	Hepatocyte growth factor	Rb	Retinoblastoma protein
HPV	Human papilloma viruses	RCHY1	Ring Finger And CHY Zinc Finger Domain Containing 1
IAV	Influenza A virus	RE	Response element
IFITM	Interferon-induced transmembrane protein	ROCK	Rho-associated protein kinase
IFNs	Interferons	ROS	Reactive oxygen species
IL-10	Interleukin-10	SAPK	Stress-activated protein kinase
IL-6	Interleukin-6	SARS-CoV	Severe acute respiratory syndrome coronavirus
iPSCs	Induced pluripotent stem cells	shRNA	Short-hairpin Ribonucleic acid
JAK/STAT	Janus kinases/ signal transducer and activator of transcription proteins	SINE	Short Interspersed Elements
		SNP	Single-nucleotide polymorphism

A fundamental role for p53 in cell cooperation may also be inferred from the consequences of abnormal p53 activation during development. This induces congenital malformations, features of CHARGE syndrome: A disorder that affects many areas of the body (CHARGE: Coloboma, Heart defects, Atresia choanae (also known as choanal atresia), growth retardation, Genital abnormalities and Ear abnormalities) (Van Nostrand *et al*, 2014). Other pathologies from aberrant expression of p53 include premature ageing (Wu & Prives, 2018); neurodegeneration (Szybińska & Leśniak, 2017); diabetes (Kung & Murphy, 2016); cardiovascular diseases (Mak *et al*, 2017); chronic inflammation (Cooks *et al*, 2014); arthritis (Zhang *et al*, 2016) and susceptibility to infection. *TP53* is also by far the most frequently mutated gene in somatic cancer (Donehower *et al*, 2019) and germline mutations in *TP53* cause the inherited cancer predisposition disorder Li-Fraumeni Syndrome (Nichols *et al*, 2001; Olivier *et al*, 2003; Guha & Malkin, 2017).

Thus, *TP53* plays a key role in cellular cooperativity and in multiple developmental processes to ensure normal tissue function and thus organismal homeostasis (Fig 1).

p53 isoforms—a cooperative network of proteins

To date, the human *TP53* gene expresses nine mRNAs (Fig 2A) giving rise to 12 proteins (Fig 2B) (Bourdon, 2014). The p53 protein isoforms are designated FLp53 or p53, $\Delta 40$ p53, $\Delta 133$ p53 and $\Delta 160$ p53, each with C-terminal alternative splice variants α , β and γ (Fig 2). p53 products are transcribed from the P1 promoter and use the first AUG in exon 2. $\Delta 40$ p53 products are also transcribed

from the P1 promoter and use an internal ribosome entry site (Bourdon *et al*, 2005). Transcription of the $\Delta 133$ p53 and $\Delta 160$ p53 products occurs from the P2 promoter in intron 4 (Marcel *et al*, 2010a, 2010b). The C-terminal isoforms are generated by alternative splicing of intron 9, giving rise to exons 9 β and 9 γ , both of which contain stop codons preventing expression of exons 10 and 11 (Fig 2A).

A number of functional studies have shown that the isoforms have both overlapping and distinct functions with canonical p53 α . $\Delta 40$ p53 α retains the second transactivation domain and the entire DNA-binding domain, therefore, can transactivate many of the known p53 α target genes (Hafsi *et al*, 2013) and other genes, including those involved in promoting cell differentiation (Ungewitter & Scrabble, 2010). $\Delta 133$ p53 α contains most of the DNA-binding domain and can directly bind to specific DNA sequences to transactivate genes (Chen *et al*, 2009; Gong *et al*, 2015). $\Delta 133$ p53 α can also bind to co-factors that have DNA-binding ability such as Early Growth Response Protein 1 (EGR1) (Xie *et al*, 2017), p63 (Marcel *et al*, 2012), Δ Np63 (Gong *et al*, 2018) and p73 (Marcel *et al*, 2012). $\Delta 133$ p53 β has been shown to transactivate a range of genes involved in cell proliferation, angiogenesis and immune regulation (Kazantseva *et al*, 2019). There is also evidence that under different conditions, these isoforms can function in concert (Fujita *et al*, 2009; Aoubala *et al*, 2011; Bernard *et al*, 2013) or in opposition to each other (Takahashi *et al*, 2014; Slatter *et al*, 2015; Horikawa *et al*, 2017; Gong *et al*, 2020). p53 isoforms contribute to many activities attributed to p53 α , notably in cell cycle regulation and apoptosis. A comprehensive list of these contributing activities can be found in recent reviews (Jorruiz & Bourdon, 2016; Kazantseva

Figure 1. Schematic illustrating the similarities between the processes leading to cancer (Hallmarks of Cancer) and the processes involved in adapting to virus infection.

Similar hallmarks between cancer development and the cellular response to viral replication are shown in purple. These include avoiding immune cell death, immune checkpoint inhibition, promoting metabolic reprogramming, avoiding programmed cell death, overriding growth suppressors (*TP53*) and cell cycle arrest. Hallmarks specific to cancer and viral replication are represented in orange and blue respectively.

et al, 2018b; Anbarasan & Bourdon, 2019). The mechanistic basis underpinning cooperative activity probably involves hetero-oligomerization of p53 isoforms either through the oligomerization or the DNA-binding domains (Fig 2B). Hetero-oligomers formed by a combination of p53 isoforms in response to multiple and often concomitant signals may have selective interactions with promoters and with the RNA polymerase II transcription machinery (Bourdon *et al*, 2005; Chen *et al*, 2009; Fujita *et al*, 2009; Meek & Anderson, 2009; Aoubala *et al*, 2011; Bernard *et al*, 2013; Hafsi *et al*, 2013; Marcel *et al*, 2014; Gong *et al*, 2015). This flexibility of interactions is facilitated by the modular nature of the p53 isoforms conferred by differing N-terminal and C-terminal domains. These allow a broad repertoire of signals that can be integrated by p53 isoforms, fine-tuning the specificity of interactions. In addition, as p53 binds specifically with high affinity to different DNA sequences (p53 Response Elements, p53REs), which are also degenerate, the repertoire of transcriptional target genes is extended. It is estimated that there are 23,808 different ways to generate a high affinity p53RE (Khoury & Bourdon, 2011). As well as the affinity and specificity of p53 proteins for the different p53RE sequences, they are also influenced by their number, as most p53-inducible genes contain clusters of p53REs separated by 0–13 bp. This enables oligomerization and stacking of p53 proteins on DNA (Kern *et al*, 1991; Stenger *et al*, 1994; Bourdon *et al*, 1997; Vyas *et al*, 2017; Lei *et al*, 2019; Ly *et al*, 2020; Senitzki *et al*, 2021). Thus, the large variety of p53 REs and permutation of p53 isoforms allow the p53 network to regulate the

expression of a broad range of genes to maintain and restore cell and organ function and thus organismal integrity (Benito *et al*, 2011; Afek *et al*, 2020; Farkas *et al*, 2021). This would not be possible if *TP53* encoded a single protein product.

Over the past decade, using diverse human cell lines and animal models, data have consistently demonstrated that the balance of expression levels of between p53 isoforms ultimately defines the p53-mediated cell responses to different and often simultaneous input signals (reviewed in Jorruiz & Bourdon, 2016). Similar to p53 α , dysregulation of p53 isoforms has been implicated in multiple pathologies. Using animal models, including zebrafish (Chen *et al*, 2005, 2009; Davidson *et al*, 2010; Elabd *et al*, 2019; Ye *et al*, 2020), drosophila (Jassim *et al*, 2003; Dichtel-Danjoy *et al*, 2013; Kashio *et al*, 2014; Simón *et al*, 2014), pigs (Niu *et al*, 2021) and mice (Maier *et al*, 2004; Hinault *et al*, 2011; Slatter *et al*, 2011; Hamard *et al*, 2013; Senturk *et al*, 2014; Campbell *et al*, 2018; Kazantseva *et al*, 2018b), experiments have shown that aberrant expression of the isoforms leads to embryo malformation (Davidson *et al*, 2010) and other pathologies. These include premature ageing (Maier *et al*, 2004; Davidson *et al*, 2010; von Muhlinen *et al*, 2018); neurodegeneration (Medrano *et al*, 2009; Turnquist *et al*, 2016); diabetes (Hinault *et al*, 2011); cardiovascular diseases (Ye *et al*, 2020); chronic inflammation (Slatter *et al*, 2011; Campbell *et al*, 2012, 2018; Roth *et al*, 2016; Kazantseva *et al*, 2018a, 2018b, 2019; Mehta *et al*, 2018); impaired immune responsiveness (Mondal *et al*, 2013; Gong *et al*, 2015, 2016a, 2016b, 2020) and

Figure 2. Structure of the *TP53* gene, encoded transcripts (A) and proteins (B).

(A) Schematic demonstrating the *TP53* gene locus and the 9 *TP53* RNA transcripts known to be generated by alternative splicing and alternative promoter usage (P1 and P2). At the top of the figure, exons represented by blue boxes, including the regions the alternatively spliced transcripts α , β and γ variants. 5'UTR and 3'UTR are shown in orange. (B) Schematic of the canonical p53 protein and the 12 known isoforms. TAD1 Transactivation domain 1, TAD2 Transactivation domain 2, PrD Proline-rich domain, NLS nuclear localization signal, OD Oligomerization domain.

cancer (reviewed in Kazantseva *et al*, 2018b); Vieler & Sanyal 2018). Thus, not only p53 α but also the p53 network in general initiates adaptive responses at multiple levels to ensure organismal homeostasis (Fig 1).

p53, isoforms, viruses and other pathogens

Arguably, one of the most profound exogenous sources of both cellular and organismal homeostatic imbalance is infection by viruses and other pathogens. Cells need to respond to the stresses of virus replication and whole organisms to the consequences of viraemia (Fig 1). Indeed, many of the common stresses known to activate p53 are consequences of infection. p53 α was discovered as a protein in complex with SV40 large tumour (LT) antigen (Lane & Crawford, 1979) and the adenovirus (Ad) E1b55 kD protein (Linzer & Levine, 1979). Since then, the list of viruses and viral proteins that interact with (at least) p53 α has grown very extensively (Table 1) and now includes other DNA viruses such as Epstein–Barr Virus (EBV, reviewed in Chatterjee *et al*, 2019), human papilloma viruses (HPV) (Parish *et al*, 2006) and herpesviruses (Maruzuru *et al*, 2013), but also RNA viruses from many taxonomic groups. These include flaviviruses, retroviruses, influenza viruses, parvoviruses and coronaviruses (Fig 3; Table 1; reviewed in Aloni-Grinstein *et al*, 2018) all of which affect p53 function. It is interesting that most of these viral proteins bind to p53 α in the DNA-binding domain (present in all 12 isoforms) and the C terminus (Fig 3). Moreover, several of these proteins bind regions of p53 encompassed by p53 β/γ splice, suggesting that one or more p53 isoforms also interact with viral proteins. Given such diversity of viruses with different tissue tropisms and modes of replication, it seems reasonable to suggest that the evolution of the TP53 gene network has occurred in adapting to the many stresses imposed by the large variety of viruses and pathogenic microorganisms.

A survey of viruses suggests that p53 α is often targeted by viral proteins having evolved strategies to promote degradation, sequestration or to inhibit the transactivation capability of p53 α (see detailed documentation in Table 1). To sustain mass viral protein production, viruses target p53 in infected cells to override cell cycle control, promote metabolic reprogramming (Frese *et al*, 2003; Yu *et al*, 2011; Ramière *et al*, 2014; Kindrachuk *et al*, 2015; Bilz *et al*, 2018; Choi *et al*, 2020; Lacroix *et al*, 2020; Singh *et al*, 2020) and prevent premature cell death via apoptosis (reviewed in Fan *et al*, 2018). Additionally, to prevent destruction, infected cells also over-ride multiple components of the immune response including recruitment and activation of immune cells (Chua *et al*, 2014; Menendez *et al*, 2019), cytokine secretion (Machado *et al*, 2018), processing and presentation of viral peptides on the cell surface (Herzer *et al*, 2003; Wang *et al*, 2013). For an efficient productive infection to occur, it is necessary for viruses to abolish all these antiviral defence systems. If the virus fails to inactivate simultaneously all components of the antiviral defence system, a productive infection cannot proceed. By manipulating p53, viruses can control all the different systems simultaneously, emphasizing the adaptive nature of the p53 response. Thus, as might be expected, loss of the TP53 gene or reduced overall expression of p53 protein leads to marked increases in the yields of several viruses (Lu *et al*, 1999; Balachandran *et al*, 2001; Farley *et al*,

2004; Pampin *et al*, 2006; Wright & Leppard, 2013). Some examples of the integral nature of the p53 network in virus life cycles are discussed below.

A topical example of the p53 network influencing virus replication is with coronaviruses (Ma-Lauer *et al*, 2016). SARS-CoV and other coronaviruses were found to be severely inhibited in cells expressing p53 α . To circumvent p53 α , the viral non-structural protein 3 stabilizes host Ring Finger and CHY Zinc Finger Domain Containing 1 (RCHY1) protein, an E3 ubiquitin ligase that binds and promotes p53 α degradation. Of interest, RNA-seq analysis of PBMCs from SARS-CoV-2 patients showed an increase in TP53 signalling (Xiong *et al*, 2020). A number of the p53 isoforms have been implicated in modulating immune and inflammatory responses (see below), and increased mRNAs from pro-inflammatory genes were also evident in samples from infected patients (Xiong *et al*, 2020). Thus, we speculate that changes in the levels of the p53 isoforms may contribute towards the immunopathology of SARS-CoV-2 infection.

In another example, p53 and isoforms have a major impact on influenza A virus (IAV). p53 α inhibits IAV replication in cell culture (Terrier *et al*, 2012) and p53 null mice have more viraemia and lung pathology than control mice (Yan *et al*, 2015). However, when p53 α is co-expressed with p53 β , p53 α no longer inhibits IAV replication (Terrier *et al*, 2012). Co-expression of p53 α with Δ 133p53 α increases IAV replication by ~ 200 fold. Thus, the relative levels of the p53 isoforms appear to dictate the outcome of an IAV infection. In a separate study, lung cancer cells overexpressing Δ 40p53 showed that Δ 40p53 inhibited interferon-induced transmembrane protein (IFITM) expression making the cells highly susceptible to IAV infection (Wang *et al*, 2018). In addition, recent data have shown that IAV non-structural (NS1) protein and CPSF4 (cellular protein cleavage and polyadenylation specificity factor 4) interact to promote TP53 splicing to generate p53 β/γ , which together promote IAV replication (Dubois *et al*, 2019). Other IAV proteins NS5A and NS3 decrease p53 α activity by counteracting the Protein Kinase R pathway and subsequently phosphorylating eukaryotic translation initiation factor 2- α (eIF2 α), which protects against viral infection (Gong *et al*, 2004; Majumder *et al*, 2001). Of interest, eIF2 α has been implicated in promoting translation of Δ 40p53 (Bourougaa *et al*, 2010). These data indicate an interplay between p53 isoforms and viral proteins in regulating virus replication.

p53 proteins may also be important in the adenovirus life cycle. Two independent studies have showed that p53 enhanced adenovirus replication by increasing expression of late-viral genes (Royds *et al*, 2006; Wright & Leppard, 2013), despite p53 being degraded by a complex of E1b55 kD and E4orfE6 protein during the early phase of infection ((Querido *et al*, 2001); Table 1).

p53 proteins also play key roles in the replication of retroviruses, such as Human Immunodeficiency Virus (HIV-1). Once the virus enters a cell, the viral RNA genome is reverse-transcribed making several copies of linear double-strand DNA that insert into the genome of the host cells (i.e. provirus). This creates DNA breaks which activates p53 (Takaoka *et al*, 2003). At each end of the viral genome are long terminal repeats (LTR) sequences. These LTRs harbour multiple DNA-binding sites for transcription factors and chromatin remodelling proteins that are required for the regulation of viral RNA synthesis and the initiation and termination of transcription. Early studies reported that HIV-1 LTRs contain p53REs and that p53 can modulate HIV-1 LTR transcriptional

Table 1. Interaction of viral proteins with p53 and their consequences.

DNA/RNA virus	Name of virus	Viral protein	Interaction with p53/ p53 isoforms	Consequence of p53/ viral protein interaction	Ref
Double-stranded DNA virus	SV40 (John Cunningham BK virus)	T antigen	T antigen interacts with p53 and alters its ability to transactivate target genes	T antigen inhibits p53 activity Agno protein promotes p53 activity	Lane and Crawford (1979); Jenkins <i>et al</i> (1988); Jiang <i>et al</i> (1993); Darbinyan <i>et al</i> (2002)
		Agno protein	Agno protein enhances the transactivation of p53 target genes		
	High Risk Human Papillomavirus (HPV) Oncogenic	High-risk HPV E2	Interacts with p53 and induces transactivation of p53 target genes	E2 and E7 activate p53 E6 inhibits p53 activity	Seavey <i>et al</i> (1999); Parish <i>et al</i> (2006); Bernard <i>et al</i> (2011)
		High-risk HPV E6	Associated with E6AP and targets p53 for proteasome degradation		
		High-risk HPV E7	Increase p53 stability		
	Adenovirus (Oncogenic)	E1A	E1A inhibits proteasomal degradation of p53. E1A also promotes the activation of p53 target genes	E1A activates p53 E1B-55K and E4orf6 inhibit p53	Linzer and Levine (1979); Braithwaite <i>et al</i> (1990); Lowe and Ruley (1993); Nevels <i>et al</i> (1997); Martin and Berk (1998); Nakajima <i>et al</i> (1998); Royds <i>et al</i> (2006)
		E1B-55 kDa	Inhibits the activation of p53 target genes. In combination with E4orf6 promotes p53 degradation		
	Simplex virus HSV-1 or HSV-2 (non-oncogenic)	ICP0	Promotes proteasomal degradation of p53	ICP0 inhibits p53 ICP4 promotes p53 stability	Boutell and Everett (2003, 2004)
		ICP4	Promotes stabilization of p53 via post- translational modification		
	Cytomegalovirus (CMV non-oncogenic)	IE1-72	Interacts with p53 and downregulates the activation of downstream targets.	IE1-72 and IE2-86 alter the activation of p53 target genes. UL84 promotes p53 stability	Hwang <i>et al</i> (2009)
		IE2-86	Interacts with p53 and alters transactivation of p53 targets.		
		UL84	Interacts with and stabilizes p53		
	Human Herpes virus 6 (non-oncogenic/ oncogenic)	HHV-6 U14	Alters cellular localization of p53 from the cytoplasm to the nucleus.	U14 promotes p53 activity ORF-1 inhibits p53 activity	Kashanchi <i>et al</i> (1997); Takemoto <i>et al</i> (2005)
		ORF-1 (DR7)	Inhibits the activation of p53 target genes		
	Epstein-Barr Virus (EBV) (non-oncogenic/ oncogenic)	BZLF-1	Interacts with p53 and alters transactivation of p53 targets.	BZLF-1, EBNA3C and LMP-1 alter p53 activity. EBNA1 inhibits p53	Chatterjee <i>et al</i> (2019)
		EBNA1	Promotes proteasomal degradation of p53 by activating USP7.		
		EBNA3C	Alters p53 transcriptional activity either by direct		

Table 1 (continued)

DNA/RNA virus	Name of virus	Viral protein	Interaction with p53/ p53 isoforms	Consequence of p53/ viral protein interaction	Ref
	Kaposi Sarcoma-Associated Herpes virus (KSHV) (oncogenic)		interaction or via modulation of Gemim3	K8β activates p53 LANA1/2, vIRF1/3/4 and k-bZIP inhibit p53 activity	Friborg <i>et al</i> (1999); Yamanegi <i>et al</i> (2005); Lee <i>et al</i> (2009); Chen <i>et al</i> (2010); Baresova <i>et al</i> (2014); Chavoshi <i>et al</i> (2016)
		LMP-1	Inhibits transcriptional activity of p53 indirectly via NF-kB pathway, IRF5 or stimulation of A20 expression		
		LANA1 and LANA2	Interact with p53 and inhibit its transcriptional activity		
		vIRF1, vIRF3, vIRF4	Suppress p53-dependent transcription and apoptosis		
		k-bZIP	Binds the C terminus of p53 and alters p53 transcriptional activity. Recruits p53 to PML bodies.		
		K8β	Antagonizes k-bZIP and induces p53 and p21 activity		
	Vaccinia Virus (non-oncogenic)	B1R kinase	MDM2-dependent degradation of p53 despite phosphorylation at Thr18. Hyperphosphorylate p53 at Ser15 and Thr18. Alters p53 transcriptional activity	Inhibits p53 activity	Lopez-Borges and Lazo (2000); Barcia <i>et al</i> (2002); Santos <i>et al</i> (2004)
Partial double/ single-stranded DNA Virus	Hepatitis B (oncogenic)	HBx	Interacts with C terminus of p53 and the ratio of HBx:p53 alters the transcriptional activity of p53.	The ratio of HBx:p53 impacts p53 activity	Truant <i>et al</i> (1995); Wang <i>et al</i> (1995); Lee and Rho (2000)
Double-stranded RNA virus	Rotavirus (non-oncogenic)	NSP1	Initial infection: interacts with DNA-binding domain of p53, resulting in ubiquitination and degradation of p53. Late infection: NSP1-p53 interaction is reduced by an unknown mechanism resulting in stabilization of p53.	NSP1 inhibits p53 during the initial phase of the infection.	Bhowmick <i>et al</i> (2013)
	Avian Reovirus (ARV)	ARV σC	Increases p53 mRNA and protein expression. Promotes p53 phosphorylation at Ser46 and Ser392.	Activates p53	Ping-Yuan <i>et al</i> (2006); Chulu <i>et al</i> (2007)
(+) Single-stranded RNA virus	Enteroviruses Poliovirus (non-oncogenic)	Viral encoded protease 3C(Pro)	Recruits p53 to PML nuclear bodies Targets p53 for degradation	Inhibits p53 activity	Weidman <i>et al</i> (2001)
	Flavivirus Dengue Virus (non-oncogenic)	DENV2	DENV2 upregulates p53-2 (p53 paralogue in mosquitoes)	Activates p53	Chen <i>et al</i> (2018)

Table 1 (continued)

DNA/RNA virus	Name of virus	Viral protein	Interaction with p53/ p53 isoforms	Consequence of p53/ viral protein interaction	Ref
	Flavivirus Zika Virus (non-oncogenic)	ZIKV-Env	Promotes phosphorylation of p53 at Ser15 and increases p53 levels during ZIKV infection	Activates p53	Ghouzzi <i>et al</i> (2016)
	Flavivirus West Nile Virus (non-oncogenic)	WNVCP	Promotes p53 stabilization	Activates p53	Yang <i>et al</i> (2008)
	Hepatitis C Virus (non-oncogenic/ oncogenic)	NS5A and NS3	Directly binds with the C terminus of p53 and prevents its transcriptional activity. Alters post-translational modification of p53. Enhances MDM2-mediated proteasomal degradation of p53.	NS5A and NS3: Low levels activate p53 while high levels inhibit p53.	Otsuka <i>et al</i> (2000); Lan <i>et al</i> (2002); Deng <i>et al</i> (2006); Bittar <i>et al</i> (2013)
		NS2	Modulates p53 function by altering the cellular localization of p53	NS2: Inhibits p53 activity.	
	Coronavirus SARS-CoV (COVID-19) MERS (non-oncogenic)	SUD	Increases ubiquitin-mediated degradation of p53	SARS-CoV-infected cells degrade p53. SARS-CoV-infected cells express the C-terminal alternative splice variant of the p53.	Leong <i>et al</i> (2005); Ma-Lauer <i>et al</i> (2016); Xiong <i>et al</i> (2020)
		PL(pro)	Increases ubiquitin-mediated degradation of p53		
		PLP2 (HCoV-NL63)	Increases ubiquitin-mediated degradation of p53		
(–) Single-stranded RNA virus	Orthomyxoviridae Influenza (non-oncogenic)	IAV	Activates p53. Alters cellular localization of p53. Results in downregulation of host p53 pathways.	p53 is elevated at the beginning of infection and during the middle-late stage of infection.	Terrier <i>et al</i> (2012); Dubois <i>et al</i> (2019)
		NS1	Alters p53 splicing in combination with CPSF4. It favours the beta and gamma splice variants. Inhibits p53 transcriptional activity. Targets MDM2 and thus contributes towards p53 stability. Facilitates phosphorylation of p53 at ser46 and ser37 contributing to apoptosis		
	Respiratory Syncytial Virus (non-oncogenic)	NS1 and NS2	Inhibit p53 activity by promoting proteasome-dependent p53 degradation at late stages of infection.	Modulates p53 activity	Bian <i>et al</i> (2012); Machado <i>et al</i> (2018)
		RSV-M	RSV-M induced p53 and p32 accumulation to induce cell cycle arrest		
	Parainfluenza virus (non-oncogenic)	dsRNA	Presence of dsRNA can trigger downregulation of p53	Modulates p53 activity	Marques <i>et al</i> (2005)

Table 1 (continued)

DNA/RNA virus	Name of virus	Viral protein	Interaction with p53/ p53 isoforms	Consequence of p53/ viral protein interaction	Ref
	Measles virus (non-oncogenic)	Measles virus V	Directly interacts with DNA-binding domain of p53 and its family member p73 to delay apoptosis	Modulates p53 and p73 activity	Cruz <i>et al</i> (2006)
Single stranded RNA-Retrovirus	HIV-1 and HIV-2 (non-oncogenic)	Tat	Inhibits activation of p53 target genes, either by repressing the p53 promoter, directly binding or altering the acetylation status of p53 at Lys320.	Early infection inhibits p53 activity. Late infection activates p53.	Li <i>et al</i> (1995b); Greenway <i>et al</i> (2002); Harrod <i>et al</i> (2003); Amini <i>et al</i> (2004); Perfettini <i>et al</i> (2005); Ali <i>et al</i> (2020)
		Nef	Directly binds p53 and prevents its transcriptional activity. It also facilitates a reduction in the half-life of p53 protein		
		Vpr	Forms a ternary complex with p53 and Sp1 which enhances p21 ^{WAF1/CIP1} expression.		
		Env	Enhances p53 phosphorylation at Ser15		
	Human T-lymphotropic virus (HTLV) (oncogenic)	Tax	Stabilizes p53 but alters its transcriptional activity by the repression of phosphorylation at Ser15 and Ser392	Modulates p53 activity to induce cell cycle arrest and prevent apoptosis	Pise-Masison <i>et al</i> (2000)

activity, directly and indirectly by interacting with other transcription factors (Gualberto & Baldwin, 1995; Gualberto *et al*, 1995; Bargonetti *et al*, 1997). p53 suppresses Tat activity, a major transactivator of HIV-1 LTR, which in turn restricts HIV replication (Li *et al*, 1995a). p53 also inhibits reverse transcription of HIV-1 in non-cycling cells through the induction of the p53-regulated gene *CDKN1A* (encoding the cyclin-dependent kinase inhibitor p21) and *SAMHD1* (encoding a deoxyribonucleotide triphosphate (dNTP) triphosphohydrolase) which limits the intracellular pool of dNTP thus inhibiting reverse-transcriptase activity (Shi *et al*, 2018). In addition, reducing p53 by increasing MDM2 levels was shown to facilitate early HIV-1 replication (Breton *et al*, 2019). Recently, the impact of the different p53 isoforms on HIV-1 replication in macrophages was investigated (Breton *et al*, 2021). $\Delta 133$ p53 was found to increase HIV-1 replication by promoting phosphorylation and inactivation of SAMHD1. Conversely, p53 β inhibited viral production. Thus, as is the case with IAV, the relative balance of p53 isoform level influences the outcome of the p53-mediated anti-HIV-1 response.

During evolution, numerous retroviruses have integrated into the genome of animals and humans and the p53 network has evolved alongside to regulate transcription from these integrated sequences. About half of the human genome consists of DNA sequences derived from ancient viral infections (Lander *et al*, 2001; Venter *et al*, 2001;

Hancks & Kazazian, 2016; Kazazian & Moran, 2017; Payer & Burns, 2019). These include Endogenous RetroViruses (ERVs), Long Interspersed Elements (LINEs) and Short Interspersed Elements (SINEs), which are collectively known as transposable elements (TEs). TEs include long terminal repeats (LTRs) and encode their own reverse transcriptase and are transcribed by RNA Polymerase II (Lander *et al*, 2001). They contain transcription initiation sites, splice sites, polyadenylation sites and multiple transcription factor-binding sites, including for p53 (Cui *et al*, 2011; Hancks & Kazazian, 2016; Kazazian & Moran, 2017; Payer & Burns, 2019). TEs can also behave as enhancers and silencers, facilitate chromatin modelling and promote chromosome rearrangements (Cui *et al*, 2011; Hancks & Kazazian, 2016; Kazazian & Moran, 2017; Payer & Burns, 2019). The millions of TEs dispersed throughout the genome have contributed to evolution by providing an abundant source of novel protein coding and DNA regulatory sequences (Cui *et al*, 2011; Hancks & Kazazian, 2016; Kazazian & Moran, 2017; Payer & Burns, 2019). Several studies have identified p53REs in the 5'UTRs of these TEs and that p53 can facilitate long distance transcriptional regulation either directly or via inducing transcription of enhancer RNAs (eRNAs). These are important for maintaining an open chromatin state readily accessible to transcription factors and cofactors and are cell-lineage specific. eRNAs function in *cis* to contribute to the dynamic stabilization of enhancer-promoter looping and in *trans* to regulate

Figure 3. Map illustrating regions on p53 protein that are bound by viral proteins post infection.

Schematic of the canonical p53 protein and the 12 known isoforms. TAD1 Transactivation domain 1, TAD2 Transactivation domain 2, PrD Proline-rich domain, NLS nuclear localization signal, OD Oligomerization domain. The horizontal bars at the bottom show the amino acids (aa) bound by viral proteins on p53 and the overlap with potential p53 protein isoforms.

chromatin-remodelling (Melo *et al*, 2013; Allen *et al*, 2014; Léveillé *et al*, 2015; Sartorelli & Lauberth, 2020). Interestingly, it has been demonstrated that p53α homotetramers induced eRNA transcription and G₁ cell cycle arrest upon treatment of MCF10A cells with the p53 agonist, nutlin (Levandowski *et al*, 2021). In contrast, Δ40p53α: p53α heterotetramers inhibited eRNA transcription and increased transcription of genes essential for cell cycle progression, including those in the E2F, mTOR and IGF-1 signalling pathways. This study demonstrates that the combination of p53 isoforms can influence the expression of TEs and eRNAs, altering the response to stress.

TE-derived *cis*-regulatory sequences also enable p53 to have chromatin pioneering activity that allows p53 to initiate novel gene expression programmes (Sammons *et al*, 2015; Yu & Buck, 2019). This could include antiviral and tumour-suppressive activities or oncogenic and anti-inflammatory activities or the generation of neo-antigens (Levine *et al*, 2016; Wylie *et al*, 2016; Buzdin *et al*, 2017; Lemaître *et al*, 2017; Garcia-Montojo *et al*, 2018; Grandi & Tramontano, 2018; Tiwari *et al*, 2018; Xue *et al*, 2020; Jansz & Faulkner, 2021).

Thus, the large variety of TE-derived sequences provides a pool of potential new genes that allow organisms to adapt to many

different environmental conditions. This, combined with the remarkable diversity of p53 regulatory capabilities through p53RE sequence diversity and the isoform network, that has evolved alongside the TEs, provides a mechanism that allows p53 to trigger tailored adaptive responses to many environmental conditions, especially virus infections. In this way, p53 ensures the maintenance of organismal homeostasis.

Besides mammalian studies, p53 isoforms have also been found in the shrimp species *Litopenaeus vannamei* (Li *et al*, 2017) where they have been shown to affect not only virus replication but also the host response to infection. Two *TP53* transcripts have been identified in *L. vannamei*—the first being LvFLp53 which corresponds to human p53α, whilst the second, LvΔNp53, lacking the N-terminal 145 amino acids, corresponds to human Δ133p53α. Similar to human Δ133p53, LvΔNp53 is transcribed from an internal promoter in intron 3. LvFLp53 was found to inhibit the replication of white spot syndrome virus (WSSV) whilst the replication of WSSV was enhanced by LvΔNp53. Silencing of LvFLp53 increased WSSV load and higher shrimp mortality. In addition, LvFLp53 downregulated the pro-inflammatory nuclear factor kappa B (NF-κB) pathway, but LvΔNp53 increased NF-κB signalling. Thus, the relative

combination of p53 isoforms in the shrimp, as with IAV in mice, has a marked influence on the outcome of virus infection affecting both virus replication and adaptive immunity of the host.

In addition to viruses, bacteria have been found to target and inactivate p53 α . Cells infected with various species of *Chlamydia* result in induction of MDM2 (González *et al*, 2014). MDM2 is an E3 ubiquitin ligase that antagonizes p53 and causes proteasomal degradation of p53 through the activation of the MDM2-p53 axis (González *et al*, 2014). Another example of p53 modulation is from *Shigella flexneri*. Infection results in an early induction of p53 α , but the p53 response and cell death are impaired by virulence effector VirA-induced calpain protease activity that causes amino terminal cleavage of p53 α (Bergounioux *et al*, 2012). Similarly, the intracellular bacterial pathogen *Neisseria gonorrhoeae* suppresses p53 post infection of epithelial cells (Vielfort *et al*, 2013) and *Salmonella typhimurium* modulates p53 activity to favour *Salmonella* colonization (Wu *et al*, 2010). *Helicobacter pylori* (*H. pylori*) activates AKT in human gastric epithelial cells, which in turn results in phosphorylation and activation of MDM2 and subsequent inactivation of p53 α (Wei *et al*, 2010). However, *H. pylori* also induces expression of Δ 133p53 and Δ 160p53 isoforms (Wei *et al*, 2012) in gastric epithelial cells and similarly, in Mongolian gerbil, *H. pylori* infection results in an induction of Δ 153p53 mRNA (orthologous to human Δ 133p53/ Δ 160p53) (Wei *et al*, 2012). Increased Δ 133p53 isoform in turn increases NF- κ B activity and the mRNA expression of multiple downstream target genes including IL-6, Bcl-2 and IL-8 (Wei *et al*, 2012). Thus, as for viruses and several bacterial species, modulating the p53 network appears to be an integral part of the infection process and also initiating adaptive responses to ensure host survival (Fig 1).

p53, isoforms and oxidative stress

Another trigger leading to loss of homeostasis that occurs in response to pathogen infection and inflammation are reactive oxygen species (ROS) (Alfadda & Sallam, 2012). ROS are generated during mitochondrial oxidative phosphorylation. Oxidative stress occurs when there is an excessive accumulation of ROS within the cell (Sies & Jones, 2020). Oxidative stress results in macromolecular damage leading to aberrant intracellular signals to promote cell proliferation and survival at subtoxic levels, while at higher levels cause cell death or senescence (reviewed in Ray *et al*, 2012, Fig 1). It is well known that ROS activate p53 and evidence suggests that p53 isoforms define the cell response to ROS (Liu *et al*, 2008). ROS increases p53 and the 20S proteasome resulting in p53 α cleavage leading to enhanced expression of Δ 40p53, which in turn regulates p53 α 's transcriptional activity (Solomon *et al*, 2017). High ROS environments result in mitochondrial DNA damage, which can be repaired by DNA pol γ which interacts with p53 α . A recent study demonstrated that both Δ 40p53 and Δ 133p53 are present in the mitochondria and both of these interact with p53 α to form dimers and tetramers (Liu *et al*, 2017a). Interestingly, *in vitro* studies showed that p53 α and Δ 40p53 enhanced the activity of mitochondrial DNA pol γ while Δ 133p53 inhibited the activity of DNA pol γ (Liu *et al*, 2017a). Mouse embryonic fibroblasts (MEF) from Δ 122p53 mice, a transgenic mouse model of Δ 133p53 (Slatter *et al*, 2011), were also resistant to oxidative stress (Kazantseva *et al*, 2018b). Similarly, liver epithelial cells treated with oxidative stress

resulted in induction of Δ 133p53 expression which protected cells from DNA damage and facilitated their survival (Gong *et al*, 2016b). Finally, mouse cells expressing p53 Ψ , a unique p53 isoform generated due to an alternative 3' splice site in intron 6, increased mitochondrial pore permeability and ROS necessary for epithelial to mesenchymal transition (Senturk *et al*, 2014). Thus, p53 isoforms may determine the impact ROS has on cellular functions and homeostasis. Of note, p53 Ψ is not physiologically expressed in human cells. The human *TP53* gene can only express p53 Ψ as a result of mutations at the intron 6/exon 7 boundary acceptor splicing site (Senturk *et al*, 2014).

p53, isoforms and cellular senescence

Cellular senescence refers to a state of permanent proliferative arrest. It is a stress response aiming to preserve cellular and organismal homeostasis. Pathogens are known to exploit ageing cells and are able to promote persistent induction of senescence resulting in loss of homeostasis (Humphreys *et al*, 2020). Other senescent triggers include telomere attrition, oxidative stress, activated oncogenes and failure to repair DNA damage (reviewed in Vasileiou *et al*, 2019, Fig 1). Senescent cells do not proliferate but are metabolically active and are known for their increased secretory activity. Senescent cells carry out a complex pro-inflammatory response known as senescence-associated secretory phenotype (SASP), involving secretion of multiple cytokines and chemokines including IL-1 β , IL-6, IL-8 and CCL2-5 which are mediated via NF- κ B signalling. Short-term accumulation of senescent cells can be beneficial; however, chronic persistence can result in ageing and age-related pathologies (Vasileiou *et al*, 2019). Two extensively studied pathways involved in the regulation of cellular senescence include p53/p21^{cip1} (inhibits cyclin/CDK complexes) and p16^{INK4A}/Rb (CDK4 inhibitor/Retinoblastoma protein). Recent evidence suggests that p53 isoforms play an important role in cellular senescence, with the levels of p53, along with the duration and intensity of the stress, determining cell fate outcome (reviewed in Mijit *et al*, 2020). Evidence from multiple studies suggest that decreased levels of Δ 133p53 and increased p53 β are associated with promotion of cellular senescence (Gong *et al*, 2016a; Turnquist *et al*, 2016, 2019; Horikawa *et al*, 2017; von Muhlinen *et al*, 2018). Senescent CD8⁺ T lymphocytes are associated with increased p53 β expression and loss of Δ 133p53 expression. Restoration of Δ 133p53 expression in near senescent CD8⁺ T cells resulted in rescue from the senescent phenotype and extended replicative lifespan (Mondal *et al*, 2013). Similarly, near-senescent primary fibroblasts derived from Hutchinson–Gilford progeria syndrome (HGPS) patients exhibited low levels of Δ 133p53 and high levels of p53 β , while restoration of Δ 133p53 expression resulted in delaying senescence and promoting proliferation as well as repair of DNA-double strand breaks (von Muhlinen *et al*, 2018). Increased levels of p53 β and decreased levels of Δ 133p53 were also observed in colon adenomas with a senescent phenotype (Fujita *et al*, 2009). Importantly, TCR-engineered CD8⁺ T cells transduced with Δ 133p53 α acquire a long-term proliferative capacity, show superior cytokine secretion and enhanced tumour-specific killing *in vitro* and in a mouse tumour model (Legscha *et al*, 2021). Taken together, these studies suggest that Δ 133p53 is an integral component of the self-renewal process in human somatic cells.

In addition to $\Delta 133p53$ and $p53\beta$, $\Delta 40p53$ may also play a role in senescence induction. MEF cells from mice expressing p44 (mouse orthologue of $\Delta 40p53$) showed reduced proliferative capacity and were positive for senescence-associated- β -galactosidase, a marker of senescent cells (Gambino *et al*, 2013). In melanoma cells, expression of $\Delta 40p53\alpha$ was shown to inhibit the transcription of genes required for apoptosis induction including p21 and p53 upregulated modulator of apoptosis (PUMA) (Avery-Kiejda *et al*, 2008). In contrast, $p53\beta$ increased the transcription of these genes in melanoma cells (Avery-Kiejda *et al*, 2008). However, in hepatocellular carcinoma (HCC) cells, $\Delta 40p53\alpha$ was associated with a higher proportion of senescent cells (Ota *et al*, 2017). Melanoma, glioblastoma, melanocytes and fibroblast cells expressing a lentivirus encoding $\Delta 40p53\alpha$ resulted in increased levels of activated $p53\alpha$ and apoptosis in the presence of proteotoxic stress (Takahashi *et al*, 2014). These seemingly contradictory results may be explained by alterations in the relative levels of $\Delta 40p53$ and other $p53$ isoform levels that coordinate the transcriptional activity of $p53$ -regulated promoters thereby affecting cellular homeostasis (Hafsi *et al*, 2013).

p53 isoforms and regeneration

To ensure that homeostasis is restored in cells after stress, most tissues and organs undergo partial or complete regeneration. Cellular processes such as proliferation, apoptosis, differentiation and senescence occur at different stages of regeneration, which include inflammation, tissue reconstruction and remodelling; all processes known to involve $p53$ and isoforms.

There is evidence that $p53\alpha$ activities are differentially regulated during the initial phases of regeneration and at the differentiation phase (Antoniades *et al*, 1994; Wells *et al*, 2006; Pearson & Sánchez Alvarado, 2010; Yun *et al*, 2013; Charruyer *et al*, 2021). $\Delta 40p53$ and $\Delta 133p53\alpha$ play key roles in this process. Mouse embryonic stem cells (ESC) express high levels of p44 compared to other mouse tissues (Ungewitter & Scrabble, 2010), highlighting its importance during development. Ectopic expression of $\Delta 40p53$ was found to enhance the proliferative capacity of ESC by maintaining pluripotency but reducing $\Delta 40p53$ levels caused cells to differentiate. Thus, $\Delta 40p53$ controls the switch from pluripotency to differentiation. This occurs by $\Delta 40p53$ modifying the activity of $p53\alpha$ to activate differentiation genes including Oct4, Nanog and the IGF-1 receptor (Ungewitter & Scrabble, 2010). Thus, the relative amounts of $p53\alpha$ and $\Delta 40p53$ dictate the biological outcome. In contrast to ESCs, transgenic mice homozygous for the $\Delta 40p53$ isoform have a shorter lifespan, reduced cell proliferation capacity and exhibit multiple premature ageing phenotypes, and again, this is linked to IGF-1 signalling (Maier *et al*, 2004). Thus, $\Delta 40p53$ functions differently in a different cell context. Indeed, increased levels of p44 resulted in neuronal cell paraptosis and autophagy-like cell death, contributing to neurodegeneration, which is also dependent on IGF-1 signalling (Pehar *et al*, 2010). Collectively these data implicate $\Delta 40p53$ as an integral regulator of tissue regeneration through IGF-1 signalling.

Co-transfection of $\Delta 133p53\alpha$ with the Yamanaka factors in human fibroblasts significantly enhanced their reprogramming to induce pluripotent stem cells (iPSCs). The $\Delta 133p53$ -iPSC had a normal karyotype, stable microsatellite repeats and wild-type mitochondrial DNA (Horikawa *et al*, 2017; Mondal *et al*, 2018). In contrast,

iPSC generated from silencing $p53\alpha$ had significant mutations and eventually formed malignant tumours. Similarly, a separate study demonstrated that overexpression of $\Delta 133p53$ in iPSC resulted in inhibition of apoptosis, promoted DNA DSB repair foci resulting in a decrease in chromosomal aberration and an increase in reprogramming efficiency (Gong *et al*, 2016a).

In Zebrafish, the heart is able to be fully regenerated after amputation of up to 20% of the ventricle (Jopling *et al*, 2010). A recent study showed that expression of $\Delta 113p53$ (orthologue of $\Delta 133p53$) is activated in stressed cardiomyocytes in the zebrafish heart, and co-ordinates with $p53\alpha$ to promote cell survival, thus contributing to myocardial regeneration (Ye *et al*, 2020). The mechanism of zebrafish cardiac regeneration also involves the MDM2-mediated regulation of $p53\alpha$ (Shoffner *et al*, 2020). Together, the data suggest that heart regeneration might require fine-tuning of the $p53$ isoform network. These mechanisms are likely to be conserved in mammalian cells as $p53$ has been shown to regulate the cardiac transcriptome in mice (Mak *et al*, 2017; Xiao *et al*, 2017).

$p53$ isoforms may also be involved in brain cell regeneration. Seminal studies indicated that $p53$ activity is increased in neuron precursors of the developing mouse brain, while $p53$ activity is reduced in neurons undergoing terminal differentiation (Rogel *et al*, 1985; Schmid *et al*, 1991). Moreover, several $p53$ isoforms are expressed in normal human foetal brain (Bourdon *et al*, 2005). Using mouse and zebrafish models, several studies have demonstrated that the regenerative capacity of neural precursor and axon regeneration is regulated by altering the $p53$ isoform ratio. During ageing, this regulatory mechanism deteriorates, resulting in disruptions in the ability of stem cells to proliferate leading to neurodegeneration (Medrano *et al*, 2009; Ungewitter & Scrabble, 2010; Takahashi *et al*, 2013; Zhao *et al*, 2021). Interestingly, as in heart regeneration, the MDM2 pathway controls $p53$ network activity in axonal regeneration, sprouting and functional recovery after brain injury (Joshi *et al*, 2015).

Furthermore, highlighting the importance of the $p53$ isoform network, primary human astrocytes undergoing cellular senescence showed diminished expression of $\Delta 133p53$ and increased expression of $p53\beta$, while restoring expression of $\Delta 133p53$ in neurotoxic astrocytes induced neurotrophic growth factors and repressed SASP, resulting in neuroprotection (Turnquist *et al*, 2016, 2019). In addition, overexpression of $\Delta 133p53\beta$ in breast cancer cells also promotes a cancer stem cell phenotype by increasing the levels of differentiation gene products *SOX 2*, *OCT3/4* and *NANOG* (Arsic *et al*, 2015). Finally, mouse cells expressing $p53\Psi$ are able to reprogramme cells to promote an invasive phenotype (Senturk *et al*, 2014). These studies show that $p53$ and isoforms contribute to several processes involved in tissue regeneration to maintain cellular and organismal homeostasis.

p53, isoforms and the immune response

As well as regulating cellular homeostatic processes in response to a variety of stresses, there is considerable evidence that $p53$ and isoforms are central to organismal homeostasis by virtue of regulating the immune response ((Jorruiz & Bourdon, 2016), Fig 1). Indeed, the data from the shrimp (Li *et al*, 2017) indicate that altering the pattern of isoform expression shifts the balance of the $p53$ network

from regulating cellular homeostasis (controlling virus replication by LvFLp53) to organismal homeostasis (controlling inflammation by Lv Δ Np53). Similarly, a role for Δ 133p53 in influencing the immune response comes from the observation that single-nucleotide polymorphism (SNP) combinations in the *Δ133TP53* promoter/enhancer region (Marcel *et al*, 2010b) are linked with elevated *Δ133TP53* mRNA levels that are strongly associated with infiltration of immunosuppressive cells in several types of human cancers (Eiholzer *et al*, 2020). Prostate and brain cancers with elevated *Δ133TP53* mRNA levels have increased the numbers of immunosuppressive macrophages and CD4⁺ T cells (Kazantseva *et al*, 2018a, 2019) and have high levels of Programmed Cell Death 1 Ligand 1 (PD-L1), encoding one of the surface molecules that inhibit anti-tumour T-cell responses (Karwacz *et al*, 2011). Moreover, Δ 133p53 β was found to directly increase PD-L1 mRNA and protein in engineered cell lines (Kazantseva *et al*, 2019).

In addition, p53-null mice show increased susceptibility to inflammation, auto-immunity and cancer (Donehower *et al*, 1992; Okuda *et al*, 2003; Zheng *et al*, 2005; Guo *et al*, 2017) and various studies have shown that loss of p53 in myeloid cells can promote an immunosuppressive environment (Lowe & Ruley, 1993; Zheng *et al*, 2005; Guo *et al*, 2017). Other studies have shown that p53 limits T-cell proliferation (Watanabe *et al*, 2014) and deletion of p53 in T cells results in an inflammatory phenotype and spontaneous autoimmunity (Zhang *et al*, 2011; Kawashima *et al*, 2013). Δ 133p53 and p53 β appear to be physiological regulators of proliferation and senescence in human T cells (Mondal *et al*, 2013), and when engineered to express Δ 133p53 α , there was reduced cell surface expression of PD-1 and TIGIT (T-cell immunoreceptor with Ig and ITIM domains) (Legscha *et al*, 2018). In a follow-up study, this group also showed that the engineered T cells had a lower frequency of senescent-like CD57⁺ and CD160⁺CD8⁺ T cells and an increased number of less differentiated CD28⁺ T cells (Legscha *et al*, 2021). These cells also had enhanced proliferative capacity, elevated cytokine secretion, similar to Δ 122p53 mice (Slatter *et al*, 2011; Roth *et al*, 2016) and improved T-cell killing. The above studies provide compelling evidence that p53 and its isoforms play important roles in modulating different aspects of the immune response, and indeed, they may be essential for sustaining a T-cell response. Thus, the p53 network is a key component of immune system homeostasis (Fig 1).

p53, isoforms and inflammatory signalling

Nuclear factor kappa B signalling

Nuclear factor kappa B (NF- κ B) is a family of transcription factors that regulate a large number of genes involved in immune processes. Well-recognized functions of NF- κ B are induction of pro-inflammatory genes in innate immune cells, regulating T-cell activation, differentiation and effector function and activation of inflammasomes (reviewed in Liu *et al*, 2017b). Thus, it is not surprising that perturbation of NF- κ B signalling results in chronic inflammatory disease (Pasparakis, 2009). It is well established that p53 inhibits inflammation by acting as an antagonist of NF- κ B (Komarova *et al*, 2005; Carrà *et al*, 2020), although co-operation between p53 α and NF- κ B has also been reported (Schneider *et al*, 2010; Liang *et al*, 2013; Iannetti *et al*, 2014; Lowe *et al*, 2014;

Machado *et al*, 2018; Carrà *et al*, 2020), but this may vary depending on the cell type and stress stimulus. The cross talk between p53 and NF- κ B may also be modulated by a common SNP in the human *TP53* gene, resulting in either proline or arginine at position 72 of p53 (Luo *et al*, 2001). Transgenic mouse studies showed increased NF- κ B-dependent inflammatory gene expression with the proline variant of p53 and enhanced response to lipopolysaccharide challenge (Luo *et al*, 2001). These residues overlap with a p53-responsive enhancer/promoter in human *TP53* gene, which in combination with SNPs in the 3'UTR of the *Δ133TP53* transcript, are associated with increased *Δ133TP53* transcription (Mechanic *et al*, 2007; Bellini *et al*, 2010; Eiholzer *et al*, 2020). These data further suggest that p53 isoforms play an important role in the cross-talk between p53 and NF- κ B pathways. Powerful evidence for this comes from the studies conducted in *H. pylori*-infected gastric cancer (Wei *et al*, 2010, 2012; Zhang *et al*, 2017). These studies showed that both NF- κ B and Δ 133p53 are upregulated and play an important role in the development of gastritis and gastric cancer (Wei *et al*, 2010, 2012; Zhang *et al*, 2017). Moreover, they also demonstrated that the inhibition of NF- κ B p65 subunit resulted in down-regulation of Δ 133p53 expression and prevented proliferation, further reinforcing the cross-talk between Δ 133p53 and NF- κ B in gastritis-associated cancer (Zhang *et al*, 2017). Another study found that Δ 133p53 levels were elevated and p53 β levels reduced in gastric adenocarcinomas compared to atrophic and superficial gastritis (Ji *et al*, 2015). The Δ 122p53 mice also showed elevated levels of multiple serum cytokines including IL-6 that are downstream targets of the NF- κ B and JAK/STAT3 pathways (Campbell *et al*, 2018). Moreover, the deletion of IL-6 in these mice reduced the incidence of tumours and metastatic frequency. These data not only show that Δ 133p53 increases NF- κ B signalling, but that sustained expression and the resulting inflammation have pathological consequences.

Serine and arginine-rich splicing factor 1 (SRSF1) is an essential splicing factor and changes in the expression of this protein are associated with aberrant splicing in various diseases (Zheng *et al*, 2020). SRSF1 is known to play an important role in the maintenance of genomic stability, cell viability and cell-cycle progression (Zheng *et al*, 2020). SRSF1 facilitates the production of type I IFNs recognized by the cytoplasmic pattern recognition receptor, RIG1, in psoriatic lesions (Xue *et al*, 2015). SRSF1-mediated production of type I IFNs also prevents the development of systemic lupus erythematosus (SLE) by restraining T-cell activation (Katsuyama *et al*, 2019) and is required for neuro-immune suppression of the human neurotropic JC virus (JCV) (Sariyer *et al*, 2016). Human aortic smooth muscle cells (HASMCs) expressing SRSF1 showed high levels of Δ 133p53 α isoform and SRSF1-deficient mice had lower levels of Δ 157p53 (orthologue of Δ 133p53) compared to controls. SRSF1 mediated upregulation of Δ 133p53 promotes proliferation and migration observed during wound healing by inducing early growth response protein 1/Kruppel-like factor 5 (EGR1/KLF5) pathway (Xie *et al*, 2017), resulting in induction of NF- κ B. In addition, SRSF1 (and SRSF3) inhibit(s) the alternative splicing of the exon 9 β / γ of *TP53* gene preventing the induction of senescence (Tang *et al*, 2013; Marcel *et al*, 2014). Collectively these studies suggest that SRSF1 and SRSF3 are important in the mediation of cross-talk between p53 and NF- κ B pathways by regulating the ratio of Δ 133p53 to p53 β .

Interferon signalling

Interferons (IFNs) are cytokines expressed by cells as the first line of defence against viral infections during immune surveillance. IFN cytokines can be broadly classified into two classes, type I (IFN α , IFN β , IFN ϵ , IFN κ and IFN ω) and type II IFNs (IFN γ) (Platanias, 2005). Both type I and type II IFNs signal via their respective receptors by interacting with a member of the JAK family and activation of the JAK/STAT pathway (Platanias, 2005). It has been shown that p53 induces the expression of type I IFN (Muñoz-Fontela *et al*, 2016) and a number of IFN-responsive genes (Rivas *et al*, 2010) as well as multiple Toll-like receptor genes (Shatz *et al*, 2012) during IAV infection. Induction of type I IFN can promote p53 α -dependent apoptosis (Yuan *et al*, 2016; Dierckx *et al*, 2017) or senescence (Moiseeva *et al*, 2006; Kim *et al*, 2009). The regulation is complex, however, as it has also been reported that p53 α can inhibit the IFN response by inhibiting STAT1, the transcription factor required to transactivate IFN inducible genes (Cheon *et al*, 2013).

A role for p53 isoforms in IFN signalling has been indicated by several studies. The RNA helicases DHX15 (McElderry *et al*, 2019) and DDX5 (Moore *et al*, 2010) are involved in activating an innate immune response to RNA virus infections, while inducing type I and II IFN (Moore *et al*, 2010; Wang *et al*, 2015; McElderry *et al*, 2019; Zan *et al*, 2020). Of interest, *Dhx15*^{-/-} zebrafish embryos exhibited reduced expression of exons 1–4 of Zp53 and increased expression of $\Delta 113p53$ (McElderry *et al*, 2019). Moreover, in breast cancer cells, an inverse correlation was shown between p68 expression (encoded by DDX5) and $\Delta 133p53$ (Moore *et al*, 2010). $\Delta 133p53\alpha$, p68 and p53 α formed a complex and $\Delta 133p53\alpha$ inhibited the ability of p68 to stimulate p53-dependent transcription (Moore *et al*, 2010; Zan *et al*, 2020). Thus, the $\Delta 133p53$ isoform appears to negatively impact DHX15 and DDX5 regulation of IFN signalling important in antiviral immunity. However, our own studies have shown that this isoform stimulates IFN signalling. Microarray analysis of splenocytes from $\Delta 122p53$ mice showed an enrichment for IFN pathways (Slatter *et al*, 2011, 2015; Campbell *et al*, 2012) and serum from the mice showed increased levels of pro-inflammatory cytokines including IL-6, TNF- α and IFN- γ and chemokines including GM-CSF and CCL2 (Slatter *et al*, 2011; Campbell *et al*, 2012, 2018). Moreover, in a subset of breast cancers with mutant p53, a bioinformatic analysis showed that $\Delta 133p53$ transcripts were associated with an IFN- γ signature and good patient prognosis (Mehta *et al*, 2018). Collectively, these results suggest that activation of IFN signalling may depend on the balance of p53 isoforms in different cell types.

JAK/STAT and Rho/ROCK signalling

The JAK/STAT signalling pathway has also been implicated in inflammation, specifically in autoimmune disease (reviewed in Banerjee *et al*, 2017). Evidence that p53 isoforms play an important role in JAK/STAT signalling comes from the $\Delta 122p53$ mouse model of $\Delta 133p53$ (Slatter *et al*, 2011; Roth *et al*, 2016; Campbell *et al*, 2018). The $\Delta 122p53$ mice developed tumours along with widespread inflammatory conditions such as lymphoid aggregates in several tissues and vasculitis. Furthermore, the serum from $\Delta 122p53$ mice showed elevated levels of multiple pro-inflammatory cytokines and chemokines as did the culture media from $\Delta 122p53$ -expressing MEFs (Slatter *et al*, 2011; Roth *et al*, 2016). MEFs expressing $\Delta 122p53$ and osteosarcoma Saos-2 cells

expressing $\Delta 133p53$ promoted invasion and metastasis which was prevented with inhibitors of both JAK/STAT and Rho/ROCK pathways (Campbell *et al*, 2018). The importance of this inflammatory signalling was further demonstrated when the mice were crossed on to an IL-6 null background. $\Delta 122p53$ mice that lacked IL-6 showed reduced activation of the JAK/STAT and Rho/ROCK signalling pathway and had a reduced incidence of tumours and metastases (Campbell *et al*, 2018). Thus, a chronic imbalance of p53 isoform may lead to malignant disease driven by inflammatory mediators. Of interest, Ewing Sarcoma cells that have elevated levels of $\Delta 133p53$ were shown to induce hepatocyte growth factor (HGF) secretion, resulting in tumour growth and metastasis (Charan *et al*, 2020) and cooperation between HGF and IL-6 resulted in proliferation and migration of myeloma cells (Hov *et al*, 2009). IL-6 is elevated in multiple cancers, is known to be involved in invasion and metastasis (Jayatilaka *et al*, 2017), promotes HGF production (Coudriet *et al*, 2010) and signals via the activation of the JAK/STAT, PI3K, MAPK and AMPK pathways in a cell type-dependent manner. Thus, $\Delta 133p53$ appears to increase the expression of signalling molecules, such as cytokines, that promote inflammation that in turn drives cancer progression via activation of JAK/STAT and Rho/ROCK signalling pathways.

Box 1. In need of answers

- 1 How is the *TP53* isoforms network regulated? What signals initiate transcription? Are there signals that activate the entire network and others that are isoform specific? Are viruses/pathogens the principal signals initiating isoform transcription and regulating function? Is Flp53 important?
- 2 What initiates *TP53* splicing? How is this regulated?
- 3 How is the *TP53* isoform network coordinated to regulate biological outcomes? How important are post-translational modifications in modulating isoform functions? How important are isoform interactions? (Some of these questions could perhaps be addressed by treating cells with different stresses accompanied by long-range RNA-sequencing and sensitive mass spectrometry).
- 4 How do the isoforms regulate downstream genes/proteins? What co-factors are required? (These questions may be addressed using ATAC-sequencing).
- 5 What are the key downstream genes targeted by one or more isoforms, which are presumably cell specific? (This question could be addressed using CRISPR/Cas9 gene knock out screens in different cells).
- 6 How do isoform functions change (i.e. the transcriptional profile) when they are encoded off a mutated *TP53* gene (as is the case in cancers and in some inflammatory disorders)? (This could be done using RNA-sequencing, comparing cells with different *TP53* mutations).
- 7 How does the *TP53* network contribute to tissue homeostasis in response to cellular stresses? What is the role of transposable elements? (Perhaps some answers to this could be obtained as under question 3 using long-range RNA sequencing).
- 8 How important are the isoforms in development, tissue regeneration and immune modulation? What are the underlying mechanisms? (These questions would need to be addressed using transgenic animals in which individual isoforms are mutated or deleted using targeted mutagenesis).

Figure 4. Model illustrating the role of the p53 network in maintaining homeostasis.

(A) Schematic showing the role of different p53 isoforms in biological processes and their influence on each other. (B) Cells and organisms are continuously exposed to stimulus from external and internal sources. Under physiological conditions, a balanced p53 network responds to these stimuli and regulates immune response and inflammation to maintain cellular and organismal homeostasis. (C) Prolonged exposure to a variety of external and internal stimuli causes an imbalance in the p53 network, which in turn results in aberrant immune response and chronic inflammation. These changes result in loss of cellular and organismal homeostasis resulting in pathologies associated with chronic diseases.

Tumour necrosis factor signalling

Another immune signalling pathway affected by p53 and isoforms is that controlled by tumour necrosis factor (TNF). TNF is a

monocyte-derived cytokine that stimulates the immune system to mount an acute phase reaction, which has the ability to destroy tumour vasculature, induce haemorrhagic necrosis and synergize

with various chemotherapeutic reagents (Balkwill, 2009). $\text{TNF}\alpha/\text{IFN}\gamma$ synergistically activates c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) to promote apoptosis of pancreatic β -cells via activation of the p53 pathway together with ROS (Kim *et al*, 2005). Studies using gastric cancer cells treated with recombinant human TNF either alone or in combination with 5-fluorouracil resulted in reduction of $\Delta 133\text{p}53$ levels and an induction of p53 α resulting in apoptosis (Shang *et al*, 2015), suggesting $\Delta 133\text{p}53$ may function to inhibit/moderate p53 α -promoted, TNF-induced apoptosis.

$\text{TNF}\alpha$ is a potent inhibitor of angiogenesis both *in vitro* and *in vivo*. Angiogenesis is essentially stimulated by the presence of hypoxic regions within a tissue and angiogenesis and inflammation are tightly linked though the functions of $\text{TNF}\alpha$ (Fiedler *et al*, 2006; Imhof & Aurrand-Lions, 2006). Which process is favoured appears to be dependent on $\text{TNF}\alpha$ concentration. p53 is known to be involved in inhibition of angiogenesis by regulation of hypoxia, inhibiting the production of pro-angiogenic factors (e.g. VEGFA) and by increasing the production of anti-angiogenic factors (e.g. MMP2) (Teodoro *et al*, 2007). On the other hand, $\Delta 133\text{p}53\alpha$ and $\Delta 133\text{p}53\beta$ both increase the levels of several angiogenic factors including VEGFA (Kazantseva *et al*, 2019) and $\Delta 133\text{p}53$ directly induces angiogenesis *in vivo* and activates distinct angiogenic signalling pathways (Bernard *et al*, 2013). In addition, abnormal angiogenesis was observed in many organs of the $\Delta 122\text{p}53$ mice in areas with inflammatory lesions (Slatter *et al*, 2011). Collectively, these data show that abnormal and sustained expression of $\Delta 133\text{p}53$ isoforms alter normal angiogenic homeostasis, which very likely promote cancer progression.

Summary

The p53 isoform field is arguably the least well-understood area of p53 biology (see also Box 1). Whilst there are many published studies implicating one or more p53 isoforms in multiple biological processes, they vary considerably in detail and there is often a paucity of mechanistic information, including how the isoforms are turned on or activated. One feature all the isoforms (except p53 Ψ) have in common is that they function as transcription factors. p53 β functions independently of p53 α and has very similar biological activities. $\Delta 40\text{p}53$ can alter p53 α to induce different gene sets from p53 α alone, but can also affect gene transcription independently of p53 α . Similarly, whilst the $\Delta 133\text{p}53$ family can modulate p53 α , it has p53 α -independent transactivation capacity with a very different transcriptional target repertoire. There is also evidence that the isoform families can modulate each other. Given this conserved ability of p53 isoforms to function as transcription factors and the many p53REs scattered throughout the human genome, present in endogenous retroviruses and other TEs, suggests that the p53 network can shape the transcriptional programme of cells. This provides an explanation for how the p53 network can contribute to multiple adaptive functions that have an impact on homeostasis in response to many input signals. An outline of such contributions where the data are available is shown in Fig 4A.

Having a single gene network regulating homeostasis ensures coordination of responses and adaptation to changing environmental conditions enabling the survival of the individual and its offspring. This is

well illustrated in how the p53 network responds to infection. Different components of the network simultaneously aid and moderate pathogen replication; alter cell physiology to cope with pathogen load; alter cell lifespan to allow pathogen replication; and trigger inflammation to limit pathogen spread. In this way, stress responses at the cellular level are linked to those at the level of the whole organism ensuring an overall homeostatic balance. As well as infection, the p53 network responds to, and influences, many fundamental responses of cells to changing environmental conditions (e.g. nutrient deprivation; changes in pH, temperature, oxygen levels, osmolarity and radiation exposure) by inducing survival, repair, proliferation, senescence, differentiation or cell death programmes and by modulating immune cell function and surveillance affecting the biology of the entire organism (Fig 1). As the p53 network is responsive to many different environmental alterations, adapting cell and tissue functions accordingly, it is necessarily very fine-tuned. Thus, it is inevitable that extended periods of imbalance in the network lead to pathology (Fig 4B and C). This is notable for the $\Delta 133\text{p}53$ isoform family which, when chronically over-expressed, promotes ageing-related conditions such as senescence, other physiological anomalies of cell migration, unchecked cell proliferation and angiogenesis, long-term inflammatory conditions and cancer. As well, chronic over-expression of $\Delta 40\text{p}53$ also results in pathology associated with reduced proliferation, senescence and ageing. Thus, the critical adaptive functions of the p53 network at the cell and organism level provide an explanation for its extraordinary conservation from relatively simple multicellular to very complex organisms.

Acknowledgements

This work was funded by the New Zealand Health Research Council Programme Grant to Braithwaite (15/500), HRC Career Development Award to Slatter (16/054), HRC Emerging First Researcher Grant to Mehta (20/638), Lottery Health Research and Matariki Diagnostics. SM and AB were also supported by funding from the Maurice Wilkins Centre for Biodiscovery. JCB was supported by a fellowship from Breast Cancer Now (2012 May SF127). CD was supported by Marsden grant (UOO1903) and Cancer Research Trust NZ.

Conflict of interest

The authors declare that they have no conflict of interest.

References

- Afek A, Shi H, Rangadurai A, Sahay H, Senitzki A, Khani S, Fang M, Salinas R, Mielko Z, Pufall MA *et al* (2020) DNA mismatches reveal conformational penalties in protein-DNA recognition. *Nature* 587: 291–296
- Alfadda AA, Sallam RM (2012) Reactive oxygen species in health and disease. *J Biomed Biotechnol* 2012: 936486
- Ali A, Farooqui SR, Rai J, Singh J, Kumar V, Mishra R, Banerjee AC (2020) HIV-1 Nef promotes ubiquitination and proteasomal degradation of p53 tumor suppressor protein by using E6AP. *Biochem Biophys Res Comm* 529: 1038–1044
- Allen MA, Andrysik Z, Dengler VL, Mellert HS, Guarnieri A, Freeman JA, Sullivan KD, Galbraith MD, Luo X, Kraus WL *et al* (2014) Global analysis of p53-regulated transcription identifies its direct targets and unexpected regulatory mechanisms. *eLife* 3: e02200

- Aloni-Grinstein R, Charni-Natan M, Solomon H, Rotter V (2018) p53 and the viral connection: back into the future (§). *Cancers* 10: 178
- Amini S, Saunders M, Kelley K, Khalili K, Sawaya BE (2004) Interplay between HIV-1 Vpr and Sp1 modulates p21WAF1 gene expression in human astrocytes. *J Biol Chem* 279: 46046–46056
- Anbarasan T, Bourdon JC (2019) The emerging landscape of p53 isoforms in physiology, cancer and degenerative diseases. *Int J Mol Sci* 20: 6257
- Antoniades HN, Galanopoulos T, Neville-Golden J, Kiritsy CP, Lynch SE (1994) p53 expression during normal tissue regeneration in response to acute cutaneous injury in swine. *J Clin Invest* 93: 2206–2214
- Aoubala M, Murray-Zmijewski F, Khoury MP, Fernandes K, Perrier S, Bernard H, Prats AC, Lane DP, Bourdon JC (2011) p53 directly transactivates $\Delta 133p53\alpha$, regulating cell fate outcome in response to DNA damage. *Cell Death Differ* 18: 248–258
- Arsic N, Gadea G, Lagerqvist EL, Busson M, Cahuzac N, Brock C, Hollande F, Gire V, Pannequin J, Roux P (2015) The p53 isoform $\Delta 133p53\beta$ promotes cancer stem cell potential. *Stem Cell Reports* 4: 531–540
- Avery-Kiejda KA, Zhang XD, Adams LJ, Scott RJ, Wojtesek B, Lane DP, Hersey P (2008) Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. *Clin Cancer Res* 14: 1659–1668
- Balachandran S, Porosnicu M, Barber GN (2001) Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. *J Virol* 75: 3474–3479
- Balkwill F (2009) Tumour necrosis factor and cancer. *Nat Rev Cancer* 9: 361–371
- Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM (2017) JAK–STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. *Drugs* 77: 521–546
- Barcia R, López-Borges S, Vega FM, Lazo PA (2002) Kinetic properties of p53 phosphorylation by the human vaccinia-related kinase 1. *Arch Biochem Biophys* 399: 1–5
- Baresova P, Musilova J, Pitha PM, Lubyova B (2014) p53 tumor suppressor protein stability and transcriptional activity are targeted by Kaposi's sarcoma-associated herpesvirus-encoded viral interferon regulatory factor 3. *Mol Cell Biol* 34: 386–399
- Bargonetti J, Chicas A, White D, Prives C (1997) p53 represses Sp1 DNA binding and HIV-LTR directed transcription. *Cell Mol Biol* 43: 935–949
- Bartas M, Brázda V, Červeň J, Pečinka P (2019) Characterization of p53 family homologs in evolutionary remote branches of Holozoa. *Int J Mol Sci* 21: 6
- Bellini I, Pitto L, Marini MG, Porcu L, Moi P, Garritano S, Boldrini L, Rainaldi G, Fontanini G, Chiarugi M et al (2010) $\Delta 133p53$ expression levels in relation to haplotypes of the TP53 internal promoter region. *Hum Mutat* 31: 456–465
- Beno I, Rosenthal K, Levine M, Shaulov L, Haran TE (2011) Sequence-dependent cooperative binding of p53 to DNA targets and its relationship to the structural properties of the DNA targets. *Nucleic Acids Res* 39: 1919–1932
- Bergounioux J, Elisee R, Prunier AL, Donnadieu F, Sperandio B, Sansonetti P, Arbibe L (2012) Calpain activation by the *Shigella flexneri* effector VirA regulates key steps in the formation and life of the bacterium's epithelial niche. *Cell Host Microbe* 11: 240–252
- Bernard H, Garmy-Susini B, Ainaoui N, Van Den Berghe L, Peurichard A, Javerzat S, Bikfalvi A, Lane DP, Bourdon JC, Prats AC (2013) The p53 isoform, $\Delta 133p53\alpha$, stimulates angiogenesis and tumour progression. *Oncogene* 32: 2150–2160
- Bernard X, Robinson P, Nominé Y, Masson M, Charbonnier S, Ramirez-Ramos JR, Deryckere F, Travé G, Orfanoudakis G (2011) Proteasomal degradation of p53 by human papillomavirus E6 oncoprotein relies on the structural integrity of p53 core domain. *PLoS One* 6: e25981
- Bhowmick R, Halder UC, Chattopadhyay S, Nayak MK, Chawla-Sarkar M (2013) Rotavirus-encoded nonstructural protein 1 modulates cellular apoptotic machinery by targeting tumor suppressor protein p53. *J Virol* 87: 6840–6850
- Bian T, Gibbs JD, Örvell C, Imani F (2012) Respiratory syncytial virus matrix protein induces lung epithelial cell cycle arrest through a p53 dependent pathway. *PLoS One* 7: e38052
- Bilz NC, Jahn K, Lorenz M, Lüdtke A, Hübschen JM, Geyer H, Mankertz A, Hübner D, Liebert UG, Claus C (2018) Rubella viruses shift cellular bioenergetics to a more oxidative and glycolytic phenotype with a strain-specific requirement for glutamine. *J Virol* 92: e00934-18
- Bittar C, Shrivastava S, Chowdhury JB, Rahal P, Ray RB (2013) Hepatitis C virus NS2 protein inhibits DNA damage pathway by sequestering p53 to the cytoplasm. *PLoS One* 8: e62581
- Bourdon JC (2014) p53 isoforms change p53 paradigm. *Mol Cell Oncol* 1: e969136
- Bourdon JC, Deguin-Chambon V, Lelong JC, Dessen P, May P, Debuire B, May E (1997) Further characterisation of the p53 responsive element—identification of new candidate genes for trans-activation by p53. *Oncogene* 14: 85–94
- Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, Saville MK, Lane DP (2005) p53 isoforms can regulate p53 transcriptional activity. *Genes Dev* 19: 2122–2137
- Bourougaa K, Naski N, Boularan C, Mlynarczyk C, Candeias MM, Marullo S, Fähræus R (2010) Endoplasmic reticulum stress induces G2 cell-cycle arrest via mRNA translation of the p53 isoform p53/47. *Mol Cell* 38: 78–88
- Boutell C, Everett RD (2003) The herpes simplex virus type 1 (HSV-1) regulatory protein ICPO interacts with and Ubiquitinates p53. *J Biol Chem* 278: 36596–36602
- Boutell C, Everett RD (2004) Herpes simplex virus type 1 infection induces the stabilization of p53 in a USP7- and ATM-independent manner. *J Virol* 78: 8068–8077
- Braithwaite A, Nelson C, Skulimowski A, McGovern J, Pigott D, Jenkins J (1990) Transactivation of the p53 oncogene by E1a gene products. *Virology* 177: 595–605
- Braithwaite AW, Prives CL (2006) p53: more research and more questions. *Cell Death Differ* 13: 877–880
- Breton Y, Barat C, Tremblay MJ (2021) The balance between p53 isoforms modulates the efficiency of HIV-1 infection in macrophages. *J Virol* 95: e0118821
- Breton Y, Desrosiers V, Ouellet M, Deshiere A, Torresilla C, Cohen ÉA, Tremblay MJ (2019) Expression of MDM2 in macrophages promotes the early postentry steps of HIV-1 infection through inhibition of p53. *J Virol* 93: e01871-18
- Buzdin AA, Prassolov V, Garazha AV (2017) Friends-enemies: endogenous retroviruses are major transcriptional regulators of human DNA. *Front Chem* 5: 35
- Campbell H, Fleming N, Roth I, Mehta S, Wiles A, Williams G, Vennin C, Arsic N, Parkin A, Pajic M et al (2018) $\Delta 133p53$ isoform promotes tumour invasion and metastasis via interleukin-6 activation of JAK-STAT and RhoA-ROCK signalling. *Nat Commun* 9: 254
- Campbell HG, Slatte TL, Jeffs A, Mehta R, Rubio C, Baird M, Braithwaite AW (2012) Does $\Delta 133p53$ isoform trigger inflammation and autoimmunity? *Cell Cycle* 11: 446–450

- Carrà G, Lingua MF, Maffeo B, Taulli R, Morotti A (2020) p53 vs NF- κ B: the role of nuclear factor-kappa B in the regulation of p53 activity and vice versa. *Cell Mol Life Sci* 77: 4449–4458
- Charan M, Dravid P, Cam M, Audino A, Gross AC, Arnold MA, Roberts RD, Cripe TP, Pertsemliadis A, Houghton PJ *et al* (2020) GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma. *Int J Cancer* 146: 3184–3195
- Charruyer A, Weisenberger T, Li H, Khalifa A, Schroeder AW, Belzer A, Ghadially R (2021) Decreased p53 is associated with a decline in asymmetric stem cell self-renewal in aged human epidermis. *Aging Cell* 20: e13310
- Chatterjee K, Das P, Chattopadhyay NR, Mal S, Choudhuri T (2019) The interplay between Epstein-Bar virus (EBV) with the p53 and its homologs during EBV associated malignancies. *Heliyon* 5: e02624
- Chavoshi S, Egorova O, Lacdao IK, Farhadi S, Sheng Y, Saridakis V (2016) Identification of Kaposi sarcoma herpesvirus (KSHV) vIRF1 protein as a novel interaction partner of human deubiquitinase USP7. *J Biol Chem* 291: 6281–6291
- Chen J, Ng SM, Chang C, Zhang Z, Bourdon J-C, Lane DP, Peng J (2009) p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. *Genes Dev* 23: 278–290
- Chen J, Ruan H, Ng SM, Gao C, Soo HM, Wu W, Zhang Z, Wen Z, Lane DP, Peng J (2005) Loss of function of def selectively up-regulates Delta113p53 expression to arrest expansion growth of digestive organs in zebrafish. *Genes Dev* 19: 2900–2911
- Chen T-H, Wu Y-J, Hou J-N, Chiang Y-H, Cheng C-C, Sifiyatun E, Chiu C-H, Wang L-C, Chen W-J (2018) A novel p53 paralogue mediates antioxidant defense of mosquito cells to survive dengue virus replication. *Virology* 519: 156–169
- Chen W, Hilton IB, Staudt MR, Burd CE, Dittmer DP (2010) Distinct p53, p53:LANA, and LANA complexes in Kaposi's sarcoma-associated herpesvirus lymphomas. *J Virol* 84: 3898–3908
- Cheon H, Holvey-Bates EG, Schoggins JW, Forster S, Hertzog P, Imanaka N, Rice CM, Jackson MW, Junk DJ, Stark GR (2013) IFN β -dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage. *EMBO J* 2: 2751–2763
- Choi UY, Lee JJ, Park A, Zhu W, Lee H-R, Choi YJ, Yoo J-S, Yu C, Feng P, Gao S-J *et al* (2020) Oncogenic human herpesvirus hijacks proline metabolism for tumorigenesis. *Proc Natl Acad Sci USA* 117: 8083–8093
- Chua CE, Chan SN, Tang BL (2014) Non-cell autonomous or secretory tumor suppression. *J Cell Physiol* 229: 1346–1352
- Chulu JL, Lee LH, Lee YC, Liao SH, Lin FL, Shih WL, Liu HJ (2007) Apoptosis induction by avian reovirus through p53 and mitochondria-mediated pathway. *Biochem Biophys Res Comm* 356: 529–535
- Cooks T, Harris CC, Oren M (2014) Caught in the cross fire: p53 in inflammation. *Carcinogenesis* 35: 1680–1690
- Coudriet GM, He J, Trucco M, Mars WM, Piganelli JD (2010) Hepatocyte growth factor modulates interleukin-6 production in bone marrow derived macrophages: implications for inflammatory mediated diseases. *PLoS One* 5: e15384
- Cruz CD, Palosaari H, Parisien JP, Devaux P, Cattaneo R, Ouchi T, Horvath CM (2006) Measles virus V protein inhibits p53 family member p73. *J Virol* 80: 5644–5650
- Cui F, Sirotni MV, Zhurkin VB (2011) Impact of Alu repeats on the evolution of human p53 binding sites. *Biology Direct* 6: 2
- Darbinyan A, Darbinian N, Safak M, Radhakrishnan S, Giordano A, Khalili K (2002) Evidence for dysregulation of cell cycle by human polyomavirus, JCV, late auxiliary protein. *Oncogene* 21: 5574–5581
- Davidson WR, Kari C, Ren Q, Daroczi B, Dicker AP, Rodeck U (2010) Differential regulation of p53 function by the N-terminal Δ Np53 and Δ 113p53 isoforms in zebrafish embryos. *BMC Dev Biol* 10: 102
- Dejosez M, Ura H, Brandt VL, Zwaka TP (2013) Safeguards for cell cooperation in mouse embryogenesis shown by genome-wide cheater screen. *Science* 341: 1511–1514
- Deng L, Nagano-Fujii M, Tanaka M, Nomura-Takigawa Y, Ikeda M, Kato N, Sada K, Hotta H (2006) NS3 protein of Hepatitis C virus associates with the tumour suppressor p53 and inhibits its function in an NS3 sequence-dependent manner. *J Gen Virol* 87: 1703–1713
- Dichtel-Danjoy M-L, Ma D, Dourlen P, Chatelain G, Napoletano F, Robin M, Corbet M, Levet C, Hafsi H, Hainaut P *et al* (2013) Drosophila p53 isoforms differentially regulate apoptosis and apoptosis-induced proliferation. *Cell Death Differ* 20: 108–116
- Dierckx T, Khouri R, Menezes SM, Decanine D, Farre L, Bittencourt A, Vandamme AM, Van Weyenbergh J (2017) IFN- β induces greater antiproliferative and proapoptotic effects and increased p53 signaling compared with IFN- α in PBMCs of adult T-cell Leukemia/Lymphoma patients. *Blood Cancer Journal* 7: e519
- Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr CA, Butel JS, Bradley A (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. *Nature* 356: 215–221
- Donehower LA, Soussi T, Korkut A, Liu Y, Schultz A, Cardenas M, Li X, Babur O, Hsu TK, Lichtarge O *et al* (2019) Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas. *Cell Rep* 28: 1370–1384.e1375
- Dubois J, Traversier A, Julien T, Padey B, Lina B, Bourdon J-C, Marcel V, Boivin G, Rosa-Calatrava M, Terrier O (2019) The Nonstructural NS1 protein of influenza viruses modulates TP53 splicing through Host Factor CPSF4. *J Virol* 93: e02168-18
- Eiholzer RA, Mehta S, Kazantseva M, Drummond CJ, McKinney C, Young K, Slater D, Morten BC, Avery-Kiejda KA, Lasham A *et al* (2020) Intronic TP53 polymorphisms are associated with increased Δ 133TP53 transcript, immune infiltration and cancer risk. *Cancers* 12: 2472
- Elabd S, Jabeen NA, Gerber V, Peravali R, Bourdon JC, Kancherla S, Vallone D, Blattner C (2019) Delay in development and behavioural abnormalities in the absence of p53 in zebrafish. *PLoS One* 14: e0220069
- Fan Y, Sanyal S, Bruzzone R (2018) Breaking bad: how viruses subvert the cell cycle. *Front Cell Infect Microbiol* 8: 396
- Farkas M, Hashimoto H, Bi Y, Davuluri RV, Resnick-Silverman L, Manfredi JJ, Debler EW, McMahon SB (2021) Distinct mechanisms control genome recognition by p53 at its target genes linked to different cell fates. *Nat Commun* 12: 484
- Farley DC, Brown JL, Leppard KN (2004) Activation of the early-late switch in adenovirus type 5 major late transcription unit expression by L4 gene products. *J Virol* 78: 1782
- Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, Gale NW, Witznath M, Rosseau S, Suttrop N *et al* (2006) Angiopoietin-2 sensitizes endothelial cells to TNF- α and has a crucial role in the induction of inflammation. *Nat Med* 12: 235–239
- Frese KK, Lee SS, Thomas DL, Latorre IJ, Weiss RS, Glaunsinger BA, Javier RT (2003) Selective PDZ protein-dependent stimulation of phosphatidylinositol 3-kinase by the adenovirus E4-ORF1 oncoprotein. *Oncogene* 22: 710–721
- Friborg J, Kong W-P, Hottiger MO, Nabel GJ (1999) p53 inhibition by the LANA protein of KSHV protects against cell death. *Nature* 402: 889–894
- Fujita K, Mondal AM, Horikawa I, Nguyen GH, Kumamoto K, Sohn JJ, Bowman ED, Mathe EA, Schetter AJ, Pine SR *et al* (2009) p53 isoforms Delta133p53

- and p53beta are endogenous regulators of replicative cellular senescence. *Nat Cell Biol* 11: 1135–1142
- Gambino V, De Michele G, Venezia O, Migliaccio P, Dall'Olio V, Bernard L, Minardi SP, Fazio MAD, Bartoli D, Servillo G et al (2013) Oxidative stress activates a specific p53 transcriptional response that regulates cellular senescence and aging. *Aging Cell* 12: 435–445
- Garcia-Montojo M, Doucet-O'Hare T, Henderson L, Nath A (2018) Human endogenous retrovirus-K (HML-2): a comprehensive review. *Crit Rev Microbiol* 44: 715–738
- Ghouzzi VE, Bianchi FT, Molineris I, Mounce BC, Berto GE, Rak M, Lebon S, Aubry L, Tocco C, Gai M et al (2016) ZIKA virus elicits P53 activation and genotoxic stress in human neural progenitors similar to mutations involved in severe forms of genetic microcephaly and p53. *Cell Death Dis* 7: e2440
- Gong G-Z, Jiang Y-F, He Y, Lai L-Y, Zhu Y-H, Su X-S (2004) HCV NS5A abrogates p53 protein function by interfering with p53-DNA binding. *World J Gastroenterol* 10: 2223
- Gong LU, Gong H, Pan X, Chang C, Ou Z, Ye S, Yin LE, Yang L, Tao T, Zhang Z et al (2015) p53 isoform $\Delta 113p53/\Delta 133p53$ promotes DNA double-strand break repair to protect cell from death and senescence in response to DNA damage. *Cell Res* 25: 351–369
- Gong L, Pan X, Chen H, Rao L, Zeng Y, Hang H, Peng J, Xiao L, Chen J (2016a) p53 isoform $\Delta 133p53$ promotes efficiency of induced pluripotent stem cells and ensures genomic integrity during reprogramming. *Sci Rep* 6: 37281
- Gong L, Pan X, Yuan ZM, Peng J, Chen J (2016b) p53 coordinates with $\Delta 133p53$ isoform to promote cell survival under low-level oxidative stress. *J Mol Cell Biol* 8: 88–90
- Gong L, Pan X, Lim CB, de Polo A, Little JB, Yuan ZM (2018) A functional interplay between $\Delta 133p53$ and $\Delta Np63$ in promoting glycolytic metabolism to fuel cancer cell proliferation. *Oncogene* 37: 2150–2164
- Gong L, Pan X, Abali GK, Little JB, Yuan ZM (2020) Functional interplay between p53 and $\Delta 133p53$ in adaptive stress response. *Cell Death Differ* 27: 1618–1632
- González E, Rother M, Kerr MC, Al-Zeer MA, Abu-Lubad M, Kessler M, Brinkmann V, Loewer A, Meyer TF (2014) Chlamydia infection depends on a functional MDM2-p53 axis. *Nat Commun* 5: 5201
- Grandi N, Tramontano E (2018) HERV envelope proteins: physiological role and pathogenic potential in cancer and autoimmunity. *Front Microbiol* 9: 462
- Greenway AL, McPhee DA, Allen K, Johnstone R, Holloway G, Mills J, Azad A, Sankovich S, Lambert P (2002) Human immunodeficiency virus type 1 Nef binds to tumor suppressor p53 and protects cells against p53-mediated apoptosis. *J Virol* 76: 2692–2702
- Gualberto A, Baldwin Jr AS (1995) p53 and Sp1 interact and cooperate in the tumor necrosis factor-induced transcriptional activation of the HIV-1 long terminal repeat. *J Biol Chem* 270: 19680–19683
- Gualberto A, Hixon ML, Finco TS, Perkins ND, Nabel GJ, Baldwin Jr AS (1995) A proliferative p53-responsive element mediates tumor necrosis factor alpha induction of the human immunodeficiency virus type 1 long terminal repeat. *Mol Cell Biol* 15: 3450–3459
- Guha T, Malkin D (2017) Inherited TP53 mutations and the Li-Fraumeni syndrome. *Cold Spring Harb Perspect Med* 7: a026187
- Guo G, Yu M, Xiao W, Celis E, Cui Y (2017) Local activation of p53 in the tumor microenvironment overcomes immune suppression and enhances antitumor immunity. *Can Res* 77: 2292–2305
- Hafner A, Bulys ML, Jambhekar A, Lahav G (2019) The multiple mechanisms that regulate p53 activity and cell fate. *Nat Rev Mol Cell Biol* 20: 199–210
- Hafsi H, Santos-Silva D, Courtois-Cox S, Hainaut P (2013) Effects of $\Delta 40p53$, an isoform of p53 lacking the N-terminus, on transactivation capacity of the tumor suppressor protein p53. *BMC Cancer* 13: 134
- Hamard P-J, Barthelery N, Hogstad B, Mungamuri SK, Tonnessen CA, Carvajal LA, Senturk E, Gillespie V, Aaronson SA, Merad M et al (2013) The C terminus of p53 regulates gene expression by multiple mechanisms in a target- and tissue-specific manner in vivo. *Genes Dev* 27: 1868–1885
- Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. *Cell* 144: 646–674
- Hancks DC, Kazanian Jr HH (2016) Roles for retrotransposon insertions in human disease. *Mobile DNA* 7: 9
- Harrod R, Nacsa J, Van Lint C, Hansen J, Karpova T, McNally J, Franchini G (2003) Human immunodeficiency virus type-1 Tat/co-activator acetyltransferase interactions inhibit p53Lys-320acetylation and p53-responsive transcription. *J Biol Chem* 278: 12310–12318
- Herzer K, Falk CS, Encke J, Eichhorst ST, Ulsenheimer A, Seliger B, Krammer PH (2003) Upregulation of major histocompatibility complex class I on liver cells by hepatitis C virus core protein via p53 and TAP1 impairs natural killer cell cytotoxicity. *J Virol* 77: 8299–8309
- Hinault C, Kawamori D, Liew CW, Maier B, Hu J, Keller SR, Mirmira RG, Scrabble H, Kulkarni RN (2011) $\Delta 40$ Isoform of p53 controls β -cell proliferation and glucose homeostasis in mice. *Diabetes* 60: 1210–1222
- Horikawa I, Park K-Y, Isogaya K, Hiyoshi Y, Li H, Anami K, Robles AI, Mondal AM, Fujita K, Serrano M et al (2017) $\Delta 133p53$ represses p53-inducible senescence genes and enhances the generation of human induced pluripotent stem cells. *Cell Death Differ* 24: 1017–1028
- Horwitz DA, Fahmy TM, Piccirillo CA, La Cava A (2019) Rebalancing immune homeostasis to treat autoimmune diseases. *Trends Immunol* 40: 888–908
- Hov H, Tian E, Holien T, Holt RU, Våtsveen TK, Fagerli UM, Waage A, Børset M, Sundan A (2009) c-Met signaling promotes IL-6-induced myeloma cell proliferation. *Eur J Haematol* 82: 277–287
- Humphreys D, ElGhazaly M, Frisan T (2020) Senescence and host-pathogen interactions. *Cells* 9: 1747
- Hwang ES, Zhang Z, Cai H, Huang DY, Huang SM, Cha CY, Huang ES (2009) Human cytomegalovirus IE1-72 protein interacts with p53 and inhibits p53-dependent transactivation by a mechanism different from that of IE2-86 protein. *J Virol* 83: 12388–12398
- Iannetti A, Ledoux AC, Tudhope SJ, Sellier H, Zhao BO, Mowla S, Moore A, Hummerich H, Gewurz BE, Cockell SJ et al (2014) Regulation of p53 and Rb links the alternative NF- κ B pathway to EZH2 expression and cell senescence. *PLoS Genet* 10: e1004642
- Imhof BA, Aurrand-Lions M (2006) Angiogenesis and inflammation face off. *Nat Med* 12: 171–172
- Jansz N, Faulkner GJ (2021) Endogenous retroviruses in the origins and treatment of cancer. *Genome Biol* 22: 147
- Jassim OW, Fink JL, Cagan RL (2003) Dmp53 protects the Drosophila retina during a developmentally regulated DNA damage response. *EMBO J* 22: 5622–5632
- Jayatilaka H, Tyle P, Chen JJ, Kwak M, Ju J, Kim HJ, Lee JSH, Wu P-H, Gilkes DM, Fan R et al (2017) Synergistic IL-6 and IL-8 paracrine signalling pathway infers a strategy to inhibit tumour cell migration. *Nat Commun* 8: 15584
- Jenkins JR, Chumakov P, Addison C, Stürzbecher HW, Wade-Evans A (1988) Two distinct regions of the murine p53 primary amino acid sequence are implicated in stable complex formation with simian virus 40 T antigen. *J Virol* 62: 3903–3906
- Ji W, Zhang N, Zhang H, Ma J, Zhong H, Jiao J, Gao Z (2015) Expression of p53 β and $\Delta 133p53$ isoforms in different gastric tissues. *Int J Clin Exp Pathol* 8: 10468–10474

- Jiang D, Srinivasan A, Lozano G, Robbins PD (1993) SV40 T antigen abrogates p53-mediated transcriptional activity. *Oncogene* 8: 2805–2812
- Jopling C, Sleep E, Raya M, Martí M, Raya A, Belmonte JCI (2010) Zebrafish heart regeneration occurs by cardiomyocyte dedifferentiation and proliferation. *Nature* 464: 606–609
- Joruz SM, Bourdon JC (2016) p53 isoforms: key regulators of the cell fate decision. *Cold Spring Harb Perspect Med* 6: a026039
- Joshi Y, Sória MG, Quadrato G, Inak G, Zhou L, Hervera A, Rathore KI, Elnaggar M, Cucchiariini M, Marine JC et al (2015) The MDM4/MDM2-p53-IGF1 axis controls axonal regeneration, sprouting and functional recovery after CNS injury. *Brain* 138: 1843–1862
- Karwacz K, Bricogne C, MacDonald D, Arce F, Bennett CL, Collins M, Escors D (2011) PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells. *EMBO Mol Med* 3: 581–592
- Kashanchi F, Araujo J, Doniger J, Muralidhar S, Hoch R, Khleif S, Mendelson E, Thompson J, Azumi N, Brady JN et al (1997) Human herpesvirus 6 (HHV-6) ORF-1 transactivating gene exhibits malignant transforming activity and its protein binds to p53. *Oncogene* 14: 359–367
- Kashio S, Obata F, Miura M (2014) Interplay of cell proliferation and cell death in Drosophila tissue regeneration. *Dev Growth Differ* 56: 368–375
- Katsuyama T, Li H, Comte D, Tsokos GC, Moulton VR (2019) Splicing factor SRSF1 controls T cell hyperactivity and systemic autoimmunity. *J Clin Invest* 129: 5411–5423
- Kawashima H, Takatori H, Suzuki K, Iwata A, Yokota M, Suto A, Minamino T, Hirose K, Nakajima H (2013) Tumor suppressor p53 inhibits systemic autoimmune diseases by inducing regulatory T cells. *J Immunol* 191: 3614–3623
- Kazantseva M, Eiholzer RA, Mehta S, Taha A, Bowie S, Roth I, Zhou J, Joruz SM, Royds JA, Hung NA et al (2018a) Elevation of the TP53 isoform $\Delta 133p53\beta$ in glioblastomas: an alternative to mutant p53 in promoting tumor development. *J Pathol* 246: 77–88
- Kazantseva M, Mehta S, Eiholzer RA, Hung N, Wiles A, Slatter TL, Braithwaite AW (2018b) A mouse model of the $\Delta 133p53$ isoform: roles in cancer progression and inflammation. *Mamm Genome* 29: 831–842
- Kazantseva M, Mehta S, Eiholzer RA, Gimenez G, Bowie S, Campbell H, Reilly-Bell AL, Roth I, Ray S, Drummond CJ et al (2019) The $\Delta 133p53\beta$ isoform promotes an immunosuppressive environment leading to aggressive prostate cancer. *Cell Death Dis* 10: 631
- Kazanian Jr HH, Moran JV (2017) Mobile DNA in health and disease. *N Engl J Med* 377: 361–370
- Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, Vogelstein B (1991) Identification of p53 as a sequence-specific DNA-binding protein. *Science* 252: 1708–1711
- Khoury MP, Bourdon JC (2011) p53 isoforms: an intracellular microprocessor? *Genes Cancer* 2: 453–465
- Kim KS, Kang KW, Seu YB, Baek SH, Kim JR (2009) Interferon-gamma induces cellular senescence through p53-dependent DNA damage signaling in human endothelial cells. *Mech Ageing Dev* 130: 179–188
- Kim WH, Lee JW, Gao B, Jung MH (2005) Synergistic activation of JNK/SAPK induced by TNF-alpha and IFN-gamma: apoptosis of pancreatic beta-cells via the p53 and ROS pathway. *Cell Signal* 17: 1516–1532
- Kindrachuk J, Ork B, Hart BJ, Mazur S, Holbrook MR, Frieman MB, Traynor D, Johnson RF, Dyall J, Kuhn JH et al (2015) Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis. *Antimicrob Agents Chemother* 59: 1088–1099
- King N, Westbrook MJ, Young SL, Kuo A, Abedin M, Chapman J, Fairclough S, Hellsten U, Isogai Y, Letunic I et al (2008) The genome of the choanoflagellate *Monosiga brevicollis* and the origin of metazoans. *Nature* 451: 783–788
- Komarova EA, Krivokrysenko V, Wang K, Neznanov N, Chernov MV, Komarov PG, Brennan M-L, Golovkina TV, Rokhlin O, Kuprash DV et al (2005) p53 is a suppressor of inflammatory response in mice. *FASEB J* 19: 1030–1032
- Kung C-P, Murphy ME (2016) The role of the p53 tumor suppressor in metabolism and diabetes. *J Endocrinol* 231: R61–R75
- Lacroix M, Riscal R, Arena G, Linares LK, Le Cam L (2020) Metabolic functions of the tumor suppressor p53: Implications in normal physiology, metabolic disorders, and cancer. *Mol Metab* 33: 2–22
- Lan K-H, Sheu M-L, Hwang S-J, Yen S-H, Chen S-Y, Wu J-C, Wang Y-J, Kato N, Omata M, Chang F-Y et al (2002) HCV NS5A interacts with p53 and inhibits p53-mediated apoptosis. *Oncogene* 21: 4801–4811
- Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W et al (2001) Initial sequencing and analysis of the human genome. *Nature* 409: 860–921
- Lane DP, Crawford LV (1979) T antigen is bound to a host protein in SV40-transformed cells. *Nature* 278: 261–263
- Lee H-R, Toth Z, Shin YC, Lee J-S, Chang H, Gu W, Oh T-K, Kim MH, Jung JU (2009) Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 4 targets MDM2 to deregulate the p53 tumor suppressor pathway. *J Virol* 83: 6739–6747
- Lee SG, Rho HM (2000) Transcriptional repression of the human p53 gene by hepatitis B viral X protein. *Oncogene* 19: 468–471
- Legscha KJ, Antunes E, Guezguez B, Theobald M, Echchannaoui H (2018) p53 isoform $\Delta 133p53a$: a novel transcriptional enhancer of T-Cell effector function to improve T-Cell based cancer immunotherapy. *Blood* 132: 3489
- Legscha KJ, Antunes Ferreira E, Chamoun A, Lang A, Awwad MHS, Ton G, Galetzka D, Guezguez B, Hundemer M, Bourdon JC et al (2021) $\Delta 133p53\alpha$ enhances metabolic and cellular fitness of TCR-engineered T cells and promotes superior antitumor immunity. *J Immunother Cancer* 9: e001846
- Lei J, Qi R, Tang Y, Wang W, Wei G, Nussinov R, Ma B (2019) Conformational stability and dynamics of the cancer-associated isoform $\Delta 133p53\beta$ are modulated by p53 peptides and p53-specific DNA. *FASEB J* 33: 4225–4235
- Lemaître C, Tsang J, Bireau C, Heidmann T, Dewannieux M (2017) A human endogenous retrovirus-derived gene that can contribute to oncogenesis by activating the ERK pathway and inducing migration and invasion. *PLoS Pathog* 13: e1006451
- Leong WF, Tan HC, Ooi EE, Koh DR, Chow VT (2005) Microarray and real-time RT-PCR analyses of differential human gene expression patterns induced by severe acute respiratory syndrome (SARS) coronavirus infection of Vero cells. *Microbes Infect* 7: 248–259
- Levandowski CB, Jones T, Gruca M, Ramamoorthy S, Dowell RD, Taatjes DJ (2021) The $\Delta 40p53$ isoform inhibits p53-dependent eRNA transcription and enables regulation by signal-specific transcription factors during p53 activation. *PLoS Biol* 19: e3001364
- Léveillé N, Melo CA, Rooijers K, Díaz-Lagares A, Melo SA, Korkmaz G, Lopes R, Moqadam FA, Maia AR, Wijchers PJ et al (2015) Genome-wide profiling of p53-regulated enhancer RNAs uncovers a subset of enhancers controlled by a lncRNA. *Nat Commun* 6: 6520
- Levine AJ, Ting DT, Greenbaum BD (2016) P53 and the defenses against genome instability caused by transposons and repetitive elements. *BioEssays* 38: 508–513
- Li CJ, Wang C, Friedman DJ, Pardee AB (1995a) Reciprocal modulations between p53 and Tat of human immunodeficiency virus type 1. *Proc Natl Acad Sci USA* 92: 5461–5464

- Li CJ, Wang C, Friedman DJ, Pardee AB (1995b) Reciprocal modulations between p53 and Tat of human immunodeficiency virus type 1. *Proc Natl Acad Sci USA* 92: 5461–5464
- Li H, Wang S, Chen Y, Lü K, Yin B, Li S, He J, Li C (2017) Identification of two p53 isoforms from *Litopenaeus vannamei* and their interaction with NF- κ B to induce distinct immune response. *Sci Rep* 7: 45821
- Liang M, Yao G, Yin M, Lü M, Tian H, Liu L, Lian J, Huang X, Sun F (2013) Transcriptional cooperation between p53 and NF- κ B p65 regulates microRNA-224 transcription in mouse ovarian granulosa cells. *Mol Cell Endocrinol* 370: 119–129
- Linzer DI, Levine AJ (1979) Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. *Cell* 17: 43–52
- Liu B, Chen Y, St Clair DK (2008) ROS and p53: a versatile partnership. *Free Radic Biol Med* 44: 1529–1535
- Liu K, Zang Y, Guo X, Wei F, Yin J, Pang L, Chen D (2017a) The Δ 133p53 isoform reduces Wtp53-induced stimulation of DNA Pol γ activity in the presence and absence of D4T. *Aging Dis* 8: 228–239
- Liu T, Zhang L, Joo D, Sun S-C (2017b) NF- κ B signaling in inflammation. *Signal Transduct Target Ther* 2: 17023
- Lopez-Borges S, Lazo PA (2000) The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-18 within the mdm-2 binding site of the p53 tumour suppressor protein. *Oncogene* 19: 3656–3664
- Lowe JM, Menendez D, Bushell PR, Shatz M, Kirk EL, Troester MA, Garantzotis S, Fessler MB, Resnick MA (2014) p53 and NF- κ B coregulate proinflammatory gene responses in human macrophages. *Can Res* 74: 2182–2192
- Lowe SW, Ruley HE (1993) Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. *Genes Dev* 7: 535–545
- Lu W, Lo SY, Chen M, Wu K, Fung YK, Ou JH (1999) Activation of p53 tumor suppressor by hepatitis C virus core protein. *Virology* 264: 134–141
- Luo JL, Yang Q, Tong WM, Hergenahm M, Wang ZQ, Hollstein M (2001) Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. *Oncogene* 20: 320–328
- Ly E, Kugel JF, Goodrich JA (2020) Single molecule studies reveal that p53 tetramers dynamically bind response elements containing one or two half sites. *Sci Rep* 10: 16176
- Machado D, Pizzorno A, Hoffmann J, Traversier A, Endtz H, Lina B, Rosa-Calatrava M, Paranhos-Baccala G, Terrier O (2018) Role of p53/NF- κ B functional balance in respiratory syncytial virus-induced inflammation response. *J Gen Virol* 99: 489–500
- Maier B, Gluba W, Bernier B, Turner T, Mohammad K, Guise T, Sutherland A, Thorner M, Scrabble H (2004) Modulation of mammalian life span by the short isoform of p53. *Genes Dev* 18: 306–319
- Majumder M, Ghosh AK, Steele R, Ray R, Ray RB (2001) Hepatitis C virus NSSA physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. *J Virol* 75: 1401–1407
- Mak TW, Hauck L, Grothe D, Billia F (2017) p53 regulates the cardiac transcriptome. *Proc Natl Acad Sci USA* 114: 2331–2336
- Ma-Lauer Y, Carbajo-Lozoya J, Hein MY, Müller MA, Deng W, Lei J, Meyer B, Kusov Y, von Brunn B, Bairad DR et al (2016) p53 down-regulates SARS coronavirus replication and is targeted by the SARS-unique domain and PLpro via E3 ubiquitin ligase RCHY1. *Proc Natl Acad Sci USA* 113: E5192–E5201
- Marcel V, Fernandes K, Terrier O, Lane DP, Bourdon JC (2014) Modulation of p53 β and p53 γ expression by regulating the alternative splicing of TP53 gene modifies cellular response. *Cell Death Differ* 21: 1377–1387
- Marcel V, Perrier S, Aoubala M, Ageorges S, Groves MJ, Diot A, Fernandes K, Tauro S, Bourdon JC (2010a) Δ 160p53 is a novel N-terminal p53 isoform encoded by Δ 133p53 transcript. *FEBS Lett* 584: 4463–4468
- Marcel V, Petit I, Murray-Zmijewski F, Gouillet de Rugy T, Fernandes K, Meuray V, Diot A, Lane DP, Aberdam D, Bourdon JC (2012) Diverse p63 and p73 isoforms regulate Δ 133p53 expression through modulation of the internal TP53 promoter activity. *Cell Death Differ* 19: 816–826
- Marcel V, Vijayakumar V, Fernández-Cuesta L, Hafsi H, Sagne C, Hautefeuille A, Olivier M, Hainaut P (2010b) p53 regulates the transcription of its Δ 133p53 isoform through specific response elements contained within the TP53 P2 internal promoter. *Oncogene* 29: 2691–2700
- Marques JT, Rebouillat D, Ramana CV, Murakami J, Hill JE, Gudkov A, Silverman RH, Stark GR, Williams BR (2005) Down-regulation of p53 by double-stranded RNA modulates the antiviral response. *J Virol* 79: 11105–11114
- Marques RE, Marques PE, Guabiraba R, Teixeira MM (2016) Exploring the homeostatic and sensory roles of the immune system. *Front Immunol* 7: 125
- Martin ME, Berk AJ (1998) Adenovirus E1B 55K represses p53 activation in vitro. *J Virol* 72: 3146–3154
- Maruzuru Y, Fujii H, Oyama M, Kozuka-Hata H, Kato A, Kawaguchi Y (2013) Roles of p53 in herpes simplex virus 1 replication. *J Virol* 87: 9323–9332
- McElderry J, Carrington B, Bishop K, Kim E, Pei W, Chen Z, Ramanagoudr-Bhojappa R, Prakash A, Burgess SM, Liu PP et al (2019) Splicing factor DHX15 affects tp53 and mdm2 expression via alternate splicing and promoter usage. *Hum Mol Genet* 28: 4173–4185
- Mechanic LE, Bowman ED, Welsh JA, Khan MA, Hagiwara N, Enewold L, Shields PG, Burdette L, Chanock S, Harris CC (2007) Common genetic variation in TP53 is associated with lung cancer risk and prognosis in African Americans and somatic mutations in lung tumors. *Cancer Epidemiol Biomarkers Prev* 16: 214–222
- Medrano S, Burns-Cusato M, Atienza MB, Rahimi D, Scrabble H (2009) Regenerative capacity of neural precursors in the adult mammalian brain is under the control of p53. *Neurobiol Aging* 30: 483–497
- Meek DW, Anderson CW (2009) Posttranslational modification of p53: cooperative integrators of function. *Cold Spring Harbor Perspect Biol* 1: a000950
- Mehta SY, Morten BC, Antony J, Henderson L, Lasham A, Campbell H, Cunliffe H, Horsfield JA, Reddel RR, Avery-Kiejda KA et al (2018) Regulation of the interferon-gamma (IFN- γ) pathway by p63 and Δ 133p53 isoform in different breast cancer subtypes. *Oncotarget* 9: 29146–29161
- Melo C, Drost J, Wijchers P, van de Werken H, de Wit E, Vrieling J, Elkon R, Melo Sónia A, Léveillé N, Kalluri R et al (2013) eRNAs are required for p53-dependent enhancer activity and gene transcription. *Mol Cell* 49: 524–535
- Menendez D, Snipe J, Marzec J, Innes CL, Polack FP, Caballero MT, Schurman SH, Kleeberger SR, Resnick MA (2019) p53-responsive TLR8 SNP enhances human innate immune response to respiratory syncytial virus. *J Clin Invest* 129: 4875–4884
- Mijit M, Caracciolo V, Melillo A, Amicarelli F, Giordano A (2020) Role of p53 in the regulation of cellular senescence. *Biomolecules* 10: 420
- Moiseeva O, Mallette FA, Mukhopadhyay UK, Moores A, Ferbeyre G (2006) DNA damage signaling and p53-dependent senescence after prolonged beta-interferon stimulation. *Mol Biol Cell* 17: 1583–1592
- Mondal AM, Horikawa I, Pine SR, Fujita K, Morgan KM, Vera E, Mazur SJ, Appella E, Vojtesek B, Blasco MA et al (2013) p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes. *J Clin Invest* 123: 5247–5257

- Mondal AM, Zhou H, Horikawa I, Supryniewicz FA, Li G, Dakic A, Rosenthal B, Ye L, Harris CC, Schlegel R et al (2018) $\Delta 133p53\alpha$, a natural p53 isoform, contributes to conditional reprogramming and long-term proliferation of primary epithelial cells. *Cell Death Dis* 9: 750
- Moore HC, Jordan LB, Bray SE, Baker L, Quinlan PR, Purdie CA, Thompson AM, Bourdon JC, Fuller-Pace FV (2010) The RNA helicase p68 modulates expression and function of the $\Delta 133$ isoform(s) of p53, and is inversely associated with $\Delta 133p53$ expression in breast cancer. *Oncogene* 29: 6475–6484
- von Muhlinen N, Horikawa I, Alam F, Isogaya K, Lissa D, Vojtesek B, Lane DP, Harris CC (2018) p53 isoforms regulate premature aging in human cells. *Oncogene* 37: 2379–2393
- Muñoz-Fontela C, Mandinova A, Aaronson SA, Lee SW (2016) Emerging roles of p53 and other tumour-suppressor genes in immune regulation. *Nat Rev Immunol* 16: 741–750
- Nakajima T, Morita K, Tsunoda H, Imajoh-Ohmi S, Tanaka H, Yasuda H, Oda K (1998) Stabilization of p53 by adenovirus E1A occurs through its amino-terminal region by modification of the ubiquitin-proteasome pathway. *J Biol Chem* 273: 20036–20045
- Nevels M, Rubenwolf S, Spruss T, Wolf H, Dobner T (1997) The adenovirus E4orf6 protein can promote E1A/E1B-induced focus formation by interfering with p53 tumor suppressor function. *Proc Natl Acad Sci USA* 94: 1206–1211
- Nichols KE, Malkin D, Garber JE, Fraumeni Jr JF, Li FP (2001) Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. *Cancer Epidemiol Biomarkers Prev* 10: 83–87
- Niu G, Hellmuth I, Flisikowska T, Pausch H, Rieblinger B, Carrapeiro A, Schade B, Böhm B, Kappe E, Fischer K et al (2021) Porcine model elucidates function of p53 isoform in carcinogenesis and reveals novel circTP53 RNA. *Oncogene* 40: 1896–1908
- Okuda Y, Okuda M, Bernard CC (2003) Regulatory role of p53 in experimental autoimmune encephalomyelitis. *J Neuroimmunol* 135: 29–37
- Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, Eeles RA (2003) Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. *Can Res* 63: 6643–6650
- Ota A, Nakao H, Sawada Y, Karnan S, Wahiduzzaman M, Inoue T, Kobayashi Y, Yamamoto T, Ishii N, Ohashi T et al (2017) $\Delta 40p53\alpha$ suppresses tumor cell proliferation and induces cellular senescence in hepatocellular carcinoma cells. *J Cell Sci* 130: 614–625
- Otsuka M, Kato N, Lan K-H, Yoshida H, Kato J, Goto T, Shiratori Y, Omata M (2000) Hepatitis C virus core protein enhances p53 function through augmentation of DNA binding affinity and transcriptional ability. *J Biol Chem* 275: 34122–34130
- Pampin M, Simonin Y, Blondel B, Percherancier Y, Chelbi-Alix MK (2006) Cross talk between PML and p53 during poliovirus infection: implications for antiviral defense. *J Virol* 80: 8582–8592
- Parish JL, Kowalczyk A, Chen HT, Roeder GE, Sessions R, Buckle M, Gaston K (2006) E2 proteins from high- and low-risk human papillomavirus types differ in their ability to bind p53 and induce apoptotic cell death. *J Virol* 80: 4580–4590
- Pasparakis M (2009) Regulation of tissue homeostasis by NF- κ B signalling: implications for inflammatory diseases. *Nat Rev Immunol* 9: 778–788
- Payer LM, Burns KH (2019) Transposable elements in human genetic disease. *Nat Rev Genet* 20: 760–772
- Pearson BJ, Sánchez Alvarado A (2010) A planarian p53 homolog regulates proliferation and self-renewal in adult stem cell lineages. *Development* 137: 213–221
- Pehar M, O'Riordan KJ, Burns-Cusato M, Andrzejewski ME, del Alcazar CG, Burger C, Scrable H, Puglielli L (2010) Altered longevity-assurance activity of p53:p44 in the mouse causes memory loss, neurodegeneration and premature death. *Aging Cell* 9: 174–190
- Perfettini J-L, Castedo M, Nardacci R, Ciccocanti F, Boya P, Roumier T, Larochette N, Piacentini M, Kroemer G (2005) Essential role of p53 phosphorylation by p38 MAPK in apoptosis induction by the HIV-1 envelope. *J Exp Med* 201: 279–289
- Ping-Yuan L, Hung-Jen L, Meng-Jiun L, Feng-Ling Y, Hsue-Yin H, Jeng-Woei L, Wen-Ling S (2006) Avian reovirus activates a novel proapoptotic signal by linking Src to p53. *Apoptosis* 11: 2179–2193
- Pise-Masison CA, Mahieux R, Radonovich M, Jiang H, Duvall J, Guillerm C, Brady J (2000) Insights into the molecular mechanism of p53 inhibition by HTLV type 1 Tax. *AIDS Res Hum Retroviruses* 16: 1669–1675
- Platanias LC (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling. *Nat Rev Immunol* 5: 375–386
- Querido E, Morrison MR, Chu-Pham-Dang H, Thirlwell SW, Boivin D, Branton PE (2001) Identification of three functions of the adenovirus e4orf6 protein that mediate p53 degradation by the E4orf6-E1B55K complex. *J Virol* 75: 699–709
- Ramière C, Rodriguez J, Enache LS, Lotteau V, André P, Diaz O (2014) Activity of hexokinase is increased by its interaction with hepatitis C virus protein NS5A. *J Virol* 88: 3246–3254
- Ray PD, Huang BW, Tsuji Y (2012) Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. *Cell Signal* 24: 981–990
- Rivas C, Aaronson SA, Munoz-Fontela C (2010) Dual role of p53 in innate antiviral immunity. *Viruses* 2: 298–313
- Rogel A, Popliker M, Webb CG, Oren M (1985) p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors. *Mol Cell Biol* 5: 2851–2855
- Roth I, Campbell H, Rubio C, Vennin C, Wilson M, Wiles A, Williams G, Woolley A, Timpson P, Berridge MV et al (2016) The $\Delta 133p53$ isoform and its mouse analogue $\Delta 122p53$ promote invasion and metastasis involving pro-inflammatory molecules interleukin-6 and CCL2. *Oncogene* 35: 4981–4989
- Royds JA, Hibma M, Dix BR, Hananeia L, Russell IA, Wiles A, Wynford-Thomas D, Braithwaite AW (2006) p53 promotes adenoviral replication and increases late viral gene expression. *Oncogene* 25: 1509–1520
- Sammons MA, Zhu J, Drake AM, Berger SL (2015) TP53 engagement with the genome occurs in distinct local chromatin environments via pioneer factor activity. *Genome Res* 25: 179–188
- Santos CR, Vega FM, Blanco S, Barcia R, Lazo PA (2004) The vaccinia virus B1R kinase induces p53 downregulation by an Mdm2-dependent mechanism. *Virology* 328: 254–265
- Sariyer R, De-Simone FI, Gordon J, Sariyer IK (2016) Immune suppression of JC virus gene expression is mediated by SRSF1. *J NeuroVirol* 22: 597–606
- Sartorelli V, Lauberth SM (2020) Enhancer RNAs are an important regulatory layer of the epigenome. *Nat Struct Mol Biol* 27: 521–528
- Schmid P, Lorenz A, Hameister H, Montenarh M (1991) Expression of p53 during mouse embryogenesis. *Development* 113: 857–865
- Schneider G, Henrich A, Greiner G, Wolf V, Lovas A, Wiczorek M, Wagner T, Reichardt S, von Werder A, Schmid RM et al (2010) Cross talk between stimulated NF- κ B and the tumor suppressor p53. *Oncogene* 29: 2795–2806
- Seavey SE, Holubar M, Saucedo LJ, Perry ME (1999) The E7 oncoprotein of human papillomavirus type 16 stabilizes p53 through a mechanism independent of p19(ARF). *J Virol* 73: 7590–7598
- Senitzki A, Safieh J, Sharma V, Golovenko D, Danin-Poleg Y, Inga A, Haran TE (2021) The complex architecture of p53 binding sites. *Nucleic Acids Res* 49: 1364–1382

- Senturk S, Yao Z, Camiolo M, Stiles B, Rathod T, Walsh AM, Nemaierova A, Lazzara MJ, Altorki NK, Krainer A et al (2014) p53 Ψ is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state. *Proc Natl Acad Sci USA* 111: E3287–96
- Shang ZM, Tang JD, Jiang QQ, Guo A, Zhang N, Gao ZX, Ji WS (2015) Role of $\Delta 133p53$ in tumor necrosis factor-induced survival of p53 functions in MKN45 gastric cancer cell line. *Eur Rev Med Pharmacol Sci* 19: 2416–2422
- Shatz M, Menendez D, Resnick MA (2012) The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells. *Can Res* 72: 3948–3957
- Shi B, Sharifi HJ, DiGrigoli S, Kinnetz M, Mellon K, Hu W, de Noronha CMC (2018) Inhibition of HIV early replication by the p53 and its downstream gene p21. *Virology* 15: 53
- Shoffner A, Cigliola V, Lee N, Ou J, Poss KD (2020) Tp53 suppression promotes cardiomyocyte proliferation during zebrafish heart regeneration. *Cell Rep* 32: 108089
- Sies H, Jones DP (2020) Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. *Nat Rev Mol Cell Biol* 21: 363–383
- Simón R, Aparicio R, Housden BE, Bray S, Busturia A (2014) Drosophila p53 controls Notch expression and balances apoptosis and proliferation. *Apoptosis* 19: 1430–1443
- Singh S, Singh PK, Suhail H, Arumugaswami V, Pellett PE, Giri S, Kumar A (2020) AMP-activated protein kinase restricts Zika virus replication in endothelial cells by potentiating innate antiviral responses and inhibiting glycolysis. *J Immunol* 204: 1810–1824
- Slatter TL, Hung N, Campbell H, Rubio C, Mehta R, Renshaw P, Williams G, Wilson M, Engelmann A, Jeffs A et al (2011) Hyperproliferation, cancer, and inflammation in mice expressing a $\Delta 133p53$ -like isoform. *Blood* 117: 5166–5177
- Slatter TL, Hung N, Bowie S, Campbell H, Rubio C, Speidel D, Wilson M, Baird M, Royds JA, Braithwaite AW (2015) $\Delta 122p53$, a mouse model of $\Delta 133p53$, enhances the tumor-suppressor activities of an attenuated p53 mutant. *Cell Death Dis* 6: e1783
- Solomon H, Bräuning B, Fainer I, Ben-Nissan G, Rabani S, Goldfinger N, Moscovitz O, Shakked Z, Rotter V, Sharon M (2017) Post-translational regulation of p53 function through 20S proteasome-mediated cleavage. *Cell Death Differ* 24: 2187–2198
- Stenger JE, Tegtmeyer P, Mayr GA, Reed M, Wang Y, Wang P, Hough PV, Mastrangelo IA (1994) p53 oligomerization and DNA looping are linked with transcriptional activation. *EMBO J* 13: 6011–6020
- Szybińska A, Leśniak W (2017) P53 dysfunction in neurodegenerative diseases - the cause or effect of pathological changes? *Aging Dis* 8: 506–518
- Takahashi R, Giannini C, Sarkaria JN, Schroeder M, Rogers J, Mastroeni D, Scrabble H (2013) p53 isoform profiling in glioblastoma and injured brain. *Oncogene* 32: 3165–3174
- Takahashi R, Markovic SN, Scrabble HJ (2014) Dominant effects of $\Delta 40p53$ on p53 function and melanoma cell fate. *J Invest Dermatol* 134: 791–800
- Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, Sasaki S, Imai K, Shibue T, Honda K et al (2003) Integration of interferon- α/β signalling to p53 responses in tumour suppression and antiviral defence. *Nature* 424: 516–523
- Takemoto M, Koike M, Mori Y, Yonemoto S, Sasamoto Y, Kondo K, Uchiyama Y, Yamanishi K (2005) Human herpesvirus 6 open reading frame U14 protein and cellular p53 interact with each other and are contained in the virion. *J Virol* 79: 13037–13046
- Tang Y, Horikawa I, Ajiro M, Robles AI, Fujita K, Mondal AM, Stauffer JK, Zheng ZM, Harris CC (2013) Downregulation of splicing factor SRSF3 induces p53 β , an alternatively spliced isoform of p53 that promotes cellular senescence. *Oncogene* 32: 2792–2798
- Teodoro JC, Evans SK, Green MR (2007) Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. *J Mol Med* 85: 1175–1186
- Terrier O, Marcel V, Cartet G, Lane DP, Lina B, Rosa-Calatrava M, Bourdon JC (2012) Influenza A viruses control expression of proviral human p53 isoforms p53 β and $\Delta 133p53$. *J Virol* 86: 8452–8460
- Tiwari B, Jones AE, Abrams JM (2018) Transposons, p53 and genome security. *Trends Genet* 34: 846–855
- Truant R, Antunovic J, Greenblatt J, Prives C, Cromlish JA (1995) Direct interaction of the hepatitis B virus HBx protein with p53 leads to inhibition by HBx of p53 response element-directed transactivation. *J Virol* 69: 1851–1859
- Turnquist C, Beck JA, Horikawa I, Obiorah IE, Von Muhlinen N, Vojtesek B, Lane DP, Grunseich C, Chahine JJ, Ames HM et al (2019) Radiation-induced astrocyte senescence is rescued by $\Delta 133p53$. *Neuro-oncology* 21: 474–485
- Turnquist C, Horikawa I, Foran E, Major EO, Vojtesek B, Lane DP, Lu X, Harris BT, Harris CC (2016) p53 isoforms regulate astrocyte-mediated neuroprotection and neurodegeneration. *Cell Death Differ* 23: 1515–1528
- Ungewitter E, Scrabble H (2010) $\Delta 40p53$ controls the switch from pluripotency to differentiation by regulating IGF signaling in ESCs. *Genes Dev* 24: 2408–2419
- Van Nostrand JL, Brady CA, Jung H, Fuentes DR, Kozak MM, Johnson TM, Lin C-Y, Lin C-J, Swiderski DL, Vogel H et al (2014) Inappropriate p53 activation during development induces features of CHARGE syndrome. *Nature* 514: 228–232
- Vasileiou PVS, Evangelou K, Vlasik K, Fildis G, Panayiotidis MI, Chronopoulos E, Passias PG, Kouloukoussa M, Gorgoulis VG, Havaki S (2019) Mitochondrial homeostasis and cellular senescence. *Cells* 8: 686
- Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, Yandell M, Evans CA, Holt RA et al (2001) The sequence of the human genome. *Science* 291: 1304–1351
- Vielor M, Sanyal S (2018) p53 isoforms and their implications in cancer. *Cancers* 10: 288
- Vielor K, Söderholm N, Weyler L, Vare D, Löfmark S, Aro H (2013) Neisseria gonorrhoeae infection causes DNA damage and affects the expression of p21, p27 and p53 in non-tumor epithelial cells. *J Cell Sci* 126: 339–347
- Vyas P, Beno I, Xi Z, Stein Y, Golovenko D, Kessler N, Rotter V, Shakked Z, Haran TE (2017) Diverse p53/DNA binding modes expand the repertoire of p53 response elements. *Proc Natl Acad Sci USA* 114: 10624–10629
- Wang B, Lam TH, Soh MK, Ye Z, Chen J, Ren EC (2018) Influenza A virus facilitates its infectivity by activating p53 to inhibit the expression of interferon-induced transmembrane proteins. *Front Immunol* 9: 1193
- Wang B, Niu D, Lai L, Ren EC (2013) p53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1. *Nat Commun* 4: 2359
- Wang P, Zhu S, Yang L, Cui S, Pan W, Jackson R, Zheng Y, Rongvaux A, Sun Q, Yang G et al (2015) Nlrp6 regulates intestinal antiviral innate immunity. *Science* 350: 826–830
- Wang XW, Gibson MK, Vermeulen W, Yeh H, Forrester K, Stürzbecher H-W, Hoeijmakers JH, Harris CC (1995) Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. *Can Res* 55: 6012–6016
- Watanabe M, Moon KD, Vacchio MS, Hathcock KS, Hodes RJ (2014) Downmodulation of tumor suppressor p53 by T cell receptor signaling is critical for antigen-specific CD4(+) T cell responses. *Immunity* 40: 681–691
- Wei J, Nagy TA, Vilgelm A, Zaika E, Ogden SR, Romero-Gallo J, Piazzuelo MB, Correa P, Washington MK, El-Rifai W et al (2010) Regulation of p53 tumor

- suppressor by *Helicobacter pylori* in gastric epithelial cells. *Gastroenterology* 139: 1333–1343
- Wei J, Noto J, Zaika E, Romero-Gallo J, Correa P, El-Rifai W, Peek RM, Zaika A (2012) Pathogenic bacterium *Helicobacter pylori* alters the expression profile of p53 protein isoforms and p53 response to cellular stresses. *Proc Natl Acad Sci USA* 109: E2543–50
- Weidman MK, Yalamanchili P, Ng B, Tsai W, Dasgupta A (2001) Poliovirus 3C protease-mediated degradation of transcriptional activator p53 requires a cellular activity. *Virology* 291: 260–271
- Wells BS, Yoshida E, Johnston LA (2006) Compensatory proliferation in *Drosophila* imaginal discs requires Dronc-dependent p53 activity. *Curr Biol* 16: 1606–1615
- Wright J, Leppard KN (2013) The human adenovirus 5 L4 promoter is activated by cellular stress response protein p53. *J Virol* 87: 11617–11625
- Wu D, Prives C (2018) Relevance of the p53–MDM2 axis to aging. *Cell Death Differ* 25: 169–179
- Wu S, Ye Z, Liu X, Zhao Y, Xia Y, Steiner A, Petrof EO, Claud EC, Sun J (2010) Salmonella typhimurium infection increases p53 acetylation in intestinal epithelial cells. *Am J Physiol Gastrointest Liver Physiol* 298: G784–G794
- Wylie A, Jones AE, D'Brot A, Lu W-J, Kurtz P, Moran JV, Rakheja D, Chen KS, Hammer RE, Comerford SA et al (2016) p53 genes function to restrain mobile elements. *Genes Dev* 30: 64–77
- Xiao Q, Zhang G, Wang H, Chen L, Lu S, Pan D, Liu G, Yang Z (2017) A p53-based genetic tracing system to follow postnatal cardiomyocyte expansion in heart regeneration. *Development* 144: 580–589
- Xie N, Chen M, Dai R, Zhang Y, Zhao H, Song Z, Zhang L, Li Z, Feng Y, Gao H et al (2017) SRSF1 promotes vascular smooth muscle cell proliferation through a $\Delta 133p53/EGR1/KLF5$ pathway. *Nat Commun* 8: 16016
- Xiong Y, Liu Y, Cao L, Wang D, Guo M, Jiang AO, Guo D, Hu W, Yang J, Tang Z et al (2020) Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. *Emerg Microbes Infect* 9: 761–770
- Xue B, Sechi LA, Kelvin DJ (2020) Human Endogenous Retrovirus K (HML-2) in health and disease. *Front Microbiol* 11: 1690
- Xue F, Li X, Zhao X, Wang L, Liu M, Shi R, Zheng J (2015) SRSF1 facilitates cytosolic DNA-induced production of type I interferons recognized by RIG-I. *PLoS One* 10: e0115354
- Yamanegi K, Tang S, Zheng Z-M (2005) Kaposi's sarcoma-associated herpesvirus K8 β is derived from a spliced intermediate of K8 pre-mRNA and antagonizes K8 α (K-bZIP) to induce p21 and p53 and blocks K8 α -CDK2 interaction. *J Virol* 79: 14207–14221
- Yan W, Wei J, Deng X, Shi Z, Zhu Z, Shao D, Li B, Wang S, Tong G, Ma Z (2015) Transcriptional analysis of immune-related gene expression in p53-deficient mice with increased susceptibility to influenza A virus infection. *BMC Med Genomics* 8: 52
- Yang M-R, Lee SR, Oh W, Lee E-W, Yeh J-Y, Nah J-J, Joo Y-S, Shin J, Lee H-W, Pyo S et al (2008) West Nile virus capsid protein induces p53-mediated apoptosis via the sequestration of HDM2 to the nucleolus. *Cell Microbiol* 10: 165–176
- Ye S, Zhao T, Zhang W, Tang Z, Gao C, Ma Z, Xiong J-W, Peng J, Tan W-Q, Chen J (2020) p53 isoform $\Delta 113p53$ promotes zebrafish heart regeneration by maintaining redox homeostasis. *Cell Death Dis* 11: 568
- Yu X, Buck MJ (2019) Defining TP53 pioneering capabilities with competitive nucleosome binding assays. *Genome Res* 29: 107–115
- Yu Y, Maguire TG, Alwine JC (2011) Human cytomegalovirus activates glucose transporter 4 expression to increase glucose uptake during infection. *J Virol* 85: 1573–1580
- Yuan XW, Huang XF, Chen ZX, Liang SG, Liao WM (2016) Interferon α sensitizes human osteosarcoma cells to doxorubicin-induced apoptosis through p53-dependent pathway. *Zhonghua Yi Xue Za Zhi* 96: 3008–3013
- Yun MH, Gates PB, Brookes JP (2013) Regulation of p53 is critical for vertebrate limb regeneration. *Proc Natl Acad Sci USA* 110: 17392–17397
- Zan J, Xu R, Tang X, Lu M, Xie S, Cai J, Huang Z, Zhang J (2020) RNA helicase DDX5 suppresses IFN-I antiviral innate immune response by interacting with PP2A-C β to deactivate IRF3. *Exp Cell Res* 396: 112332
- Zhang HM, Sang XG, Wang YZ, Cui C, Zhang L, Ji WS (2017) Role of $\Delta 133p53$ isoform in NF- κ B inhibitor PDTC-mediated growth inhibition of MKN45 gastric cancer cells. *World J Gastroenterol* 23: 2716–2722
- Zhang S, Zheng M, Kibe R, Huang Y, Marrero L, Warren S, Zieske AW, Iwakuma T, Kolls JK, Cui Y (2011) Trp53 negatively regulates autoimmunity via the STAT3-Th17 axis. *FASEB J* 25: 2387–2398
- Zhang T, Li H, Shi J, Li S, Li M, Zhang L, Zheng L, Zheng D, Tang F, Zhang X et al (2016) p53 predominantly regulates IL-6 production and suppresses synovial inflammation in fibroblast-like synoviocytes and adjuvant-induced arthritis. *Arthritis Res Ther* 18: 271
- Zhao T, Ye S, Tang Z, Guo L, Ma Z, Zhang Y, Yang C, Peng J, Chen J (2021) Loss-of-function of p53 isoform $\Delta 113p53$ accelerates brain aging in zebrafish. *Cell Death Dis* 12: 151
- Zheng SJ, Lamhamedi-Cherradi SE, Wang P, Xu L, Chen YH (2005) Tumor suppressor p53 inhibits autoimmune inflammation and macrophage function. *Diabetes* 54: 1423–1428
- Zheng X, Peng Q, Wang L, Zhang X, Huang L, Wang J, Qin Z (2020) Serine/arginine-rich splicing factors: the bridge linking alternative splicing and cancer. *Int J Biol Sci* 16: 2442–2453

License: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.